

CITATION REPORT

List of articles citing

Blood-brain barrier delivery

DOI: 10.1016/j.drudis.2006.10.013

Drug Discovery Today, 2007, 12, 54-61.

Source: <https://exaly.com/paper-pdf/42943303/citation-report.pdf>

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
923	From the liver to the brain across the blood-brain barrier. 2007 , 104, 7315-6		22
922	Brain-derived neurotrophic factor in the ventromedial nucleus of the hypothalamus reduces energy intake. 2007 , 293, R1037-45		80
921	Role of P-glycoprotein in restricting the brain penetration of tanshinone IIA, a major active constituent from the root of <i>Salvia miltiorrhiza</i> Bunge, across the blood-brain barrier. 2007 , 37, 635-78		34
920	Drug targeting to the brain. 2007 , 24, 1733-44		349
919	Challenges for blood-brain barrier (BBB) screening. 2007 , 37, 1135-51		67
918	A novel p38 alpha MAPK inhibitor suppresses brain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer's disease mouse model. 2007 , 4, 21		167
917	Tetanus toxin C fragment-conjugated nanoparticles for targeted drug delivery to neurons. 2007 , 28, 5176-84		80
916	The highly permeable blood-brain barrier: an evaluation of current opinions about brain uptake capacity. <i>Drug Discovery Today</i> , 2007 , 12, 1076-82	8.8	42
915	Endothelin-1 reduces p-glycoprotein transport activity in an in vitro model of human adult blood-brain barrier. 2008 , 28, 915-21		15
914	Nonviral approaches for neuronal delivery of nucleic acids. 2008 , 25, 983-98		103
913	<i>Griffonia simplicifolia</i> isolectin B4 identifies a specific subpopulation of angiogenic blood vessels following contusive spinal cord injury in the adult mouse. 2008 , 507, 1031-52		89
912	Genetic engineering of a lysosomal enzyme fusion protein for targeted delivery across the human blood-brain barrier. 2008 , 99, 475-84		113
911	Recent developments on 3-hydroxy-4-pyridinones with respect to their clinical applications: Mono and combined ligand approaches. 2008 , 252, 1213-1224		47
910	Prodrug approaches for CNS delivery. 2008 , 10, 92-102		110
909	Recent advances in blood-brain barrier disruption as a CNS delivery strategy. 2008 , 10, 166-77		127
908	Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2. 2008 , 155, 185-97		234
907	Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule?. 2008 , 7, 205-20		360

906	Animal models of highly pathogenic RNA viral infections: encephalitis viruses. 2008 , 78, 69-78	20
905	DARPinS: a new generation of protein therapeutics. <i>Drug Discovery Today</i> , 2008 , 13, 695-701	8.8 171
904	Preparation and brain delivery property of biodegradable polymersomes conjugated with OX26. 2008 , 128, 120-7	236
903	Strategies to assess blood-brain barrier penetration. 2008 , 3, 677-87	84
902	The blood-brain barrier in health and chronic neurodegenerative disorders. 2008 , 57, 178-201	2229
901	Polymeric nanoparticles for the drug delivery to the central nervous system. 2008 , 5, 155-74	161
900	Progress in drug delivery to the central nervous system by the prodrug approach. 2008 , 13, 1035-65	109
899	Modulation of P-glycoprotein at the blood-brain barrier: opportunities to improve central nervous system pharmacotherapy. 2008 , 60, 196-209	285
898	Toward an optimal blood-brain barrier shuttle by synthesis and evaluation of peptide libraries. 2008 , 51, 4881-9	54
897	Identification and design of peptides as a new drug delivery system for the brain. 2008 , 324, 1064-72	314
896	CNS disorders--current treatment options and the prospects for advanced therapies. 2008 , 34, 1141-67	28
895	Pharmacological demarcation of the growth hormone, gut motility and feeding effects of ghrelin using a novel ghrelin receptor agonist. 2008 , 149, 6280-8	47
894	Clinical Experience with Lapatinib in Patients with ErbB2-Overexpressing Metastatic Breast Cancer. 2008 , 3, 7-12	1
893	Local kinetics and dynamics of xenobiotics. 2008 , 38, 697-720	34
892	Nanotechnology solutions for Alzheimer's disease: advances in research tools, diagnostic methods and therapeutic agents. 2008 , 13, 199-223	79
891	Drug interactions with natural products at the blood brain barrier. 2008 , 9, 1019-26	13
890	Brain endothelial cell-cell junctions: how to "open" the blood brain barrier. 2008 , 6, 179-92	342
889	The blood-central nervous system barriers actively control immune cell entry into the central nervous system. 2008 , 14, 1555-65	114

888	Drug delivery and nanoparticles: applications and hazards. 2008 , 3, 133-49		2303
887	The nasal route as a potential pathway for delivery of erythropoietin in the treatment of acute ischemic stroke in humans. 2009 , 9, 970-81		45
886	Modular protein engineering in emerging cancer therapies. 2009 , 15, 893-916		31
885	Targeted drugs and nanomedicine: present and future. 2009 , 15, 153-72		169
884	Computational Models for Central Nervous System Penetration. 2009 , 5, 71-89		5
883	Lactoferrin-conjugated PEG-PLA nanoparticles with improved brain delivery: in vitro and in vivo evaluations. 2009 , 134, 55-61		282
882	Brain drug targeting: a computational approach for overcoming blood-brain barrier. <i>Drug Discovery Today</i> , 2009 , 14, 1030-6	8.8	52
881	P-glycoprotein deficient mouse in situ blood-brain barrier permeability and its prediction using an in combo PAMPA model. 2009 , 38, 121-37		60
880	In vivo, in vitro and in silico methods for small molecule transfer across the BBB. 2009 , 98, 4429-68		109
879	Alteration of blood-brain barrier function by methamphetamine and cocaine. 2009 , 336, 385-92		46
878	Cellular elements of the blood-brain barrier. 2009 , 34, 2067-77		112
877	Application of a Library of Artificial Receptors Formed by Self-Organization of N-Lipidated Peptides Immobilized on Cellulose for Preliminary Studies of Binding of N-Phenylpiperazines. 2009 , 28, 728-736		2
876	Classification of Blood-Brain Barrier Permeation by Kohonen's Self-Organizing Neural Network (KohNN) and Support Vector Machine (SVM). 2009 , 28, 989-994		15
875	Chemical modulators of sphingosine-1-phosphate receptors as barrier-oriented therapeutic molecules. 2009 , 8, 297-307		132
874	AZT 5'-triphosphate nanoformulation suppresses human immunodeficiency virus type 1 replication in peripheral blood mononuclear cells. 2009 , 15, 343-7		26
873	The potential for nanoparticle-based drug delivery to the brain: overcoming the blood-brain barrier. 2009 , 6, 553-65		150
872	Back-burning to cure HIV: temporary depletion of all CD4+ cells and elimination of the extracellular reservoir with HIV immunotoxin therapy. 2009 , 72, 592-5		4
871	Differential receptor-mediated drug targeting to the diseased brain. 2009 , 6, 227-37		63

870	The Cerebral Circulation. 2009 , 1, 1-59	94
869	Getting into the brain: approaches to enhance brain drug delivery. 2009 , 23, 35-58	294
868	Chapter 5 - Development of iron chelator-nanoparticle conjugates as potential therapeutic agents for Alzheimer disease. 2009 , 180, 97-108	14
867	Design, selection, and characterization of thioflavin-based intercalation compounds with metal chelating properties for application in Alzheimer's disease. 2009 , 131, 1436-51	179
866	Convection-enhanced delivery for the treatment of brain tumors. 2009 , 9, 1519-27	138
865	Integration column: biofunctional polymeric nanoparticles for spatio-temporal control of drug delivery and biomedical applications. 2009 , 1, 446-51	11
864	Preparation of a 3'-azido-3'-deoxythymidine (AZT) derivative, which is blood-brain barrier permeable. 2009 , 4669-71	11
863	[Biology of the blood-brain barrier: Part I]. 2009 , 165, 863-74	9
862	Drug transport across the blood-brain barrier and the impact of breast cancer resistance protein (ABCG2). 2009 , 9, 130-47	42
861	ABC pumps and their role in active drug transport. 2009 , 9, 119-29	52
860	Peptide-based vectors for blood-brain barrier targeting and delivery of drugs to the central nervous system. 2010 , 1, 489-94	16
859	The Role of Permeability in Drug ADME/PK, Interactions and Toxicity, and the Permeability-Based Classification System (PCS). 2010 , 367-380	1
858	RNAi-mediated barrier modulation: synergies of the brain and eye. 2010 , 1, 587-94	7
857	In vitro blood brain barrier models as a screening tool for colloidal drug delivery systems and other nanosystems. 2010 , 1, 133	5
856	Exploiting nutrient transporters at the blood-brain barrier to improve brain distribution of small molecules. 2010 , 1, 775-84	31
855	A review of multifunctional nanoemulsion systems to overcome oral and CNS drug delivery barriers. 2010 , 27, 260-73	62
854	Impact of protein binding on receptor occupancy: a two-compartment model. 2010 , 265, 657-71	11
853	Identification of peptide ligands for targeting to the blood-brain barrier. 2010 , 27, 673-82	50

852	Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases. 2010 , 37, 48-57	589
851	The role of the blood-CNS barrier in CNS disorders and their treatment. 2010 , 37, 3-12	74
850	Multimodal investigations of trans-endothelial cell trafficking under condition of disrupted blood-brain barrier integrity. 2010 , 11, 34	19
849	Lactoferrin-modified procationic liposomes as a novel drug carrier for brain delivery. 2010 , 40, 94-102	88
848	Strategy for effective brain drug delivery. 2010 , 40, 385-403	262
847	Brain-reactive autoantibodies are nearly ubiquitous in human sera and may be linked to pathology in the context of blood-brain barrier breakdown. 2010 , 1345, 221-32	94
846	Epidermal growth factor targeting of bacteriophage to the choroid plexus for gene delivery to the central nervous system via cerebrospinal fluid. 2010 , 1359, 1-13	9
845	Site-specific opening of the blood-brain barrier. 2010 , 3, 356-67	57
844	A novel vascular targeting strategy for brain-derived endothelial cells using a TCR mimic antibody. 2010 , 225, 664-72	5
843	Arsenic trioxide influences viral replication in target organs of coxsackievirus B3-infected mice. 2010 , 12, 1027-34	2
842	Trimethylated chitosan-conjugated PLGA nanoparticles for the delivery of drugs to the brain. 2010 , 31, 908-15	147
841	Transferrin-conjugated nanoparticles of poly(lactide)-D-alpha-tocopheryl polyethylene glycol succinate diblock copolymer for targeted drug delivery across the blood-brain barrier. 2010 , 31, 7748-57	169
840	Predictive screening model for potential vector-mediated transport of cationic substrates at the blood-brain barrier choline transporter. 2010 , 20, 870-7	16
839	Effectors and determinants of the innate and adaptive immune responses. 1-14	1
838	Negotiating the brain barriers:. 35-46	
837	Treatment with nasal neuro-EPO improves the neurological, cognitive, and histological state in a gerbil model of focal ischemia. 2010 , 10, 2288-300	28
836	The mouse blood-brain barrier transcriptome: a new resource for understanding the development and function of brain endothelial cells. 2010 , 5, e13741	383
835	Neurobiological alterations induced by exercise and their impact on depressive disorders [corrected]. 2010 , 6, 115-25	50

834	FEASIBILITY STUDY OF A CLINICAL BLOOD-BRAIN BARRIER OPENING ULTRASOUND SYSTEM. 2010 , 1, 309	9
833	ABC transporters and drug efflux at the blood-brain barrier. 2010 , 21, 29-53	71
832	Targeted drug delivery across the blood-brain barrier using ultrasound technique. 2010 , 1, 819-48	48
831	MR-based molecular imaging of the brain: the next frontier. 2010 , 31, 1577-83	11
830	Lipid nanoparticles: effect on bioavailability and pharmacokinetic changes. 2010 , 115-41	133
829	Application of fragment-based NMR screening, X-ray crystallography, structure-based design, and focused chemical library design to identify novel microM leads for the development of nM BACE-1 (beta-site APP cleaving enzyme 1) inhibitors. 2010 , 53, 942-50	93
828	Subtlety of the structure-affinity and structure-efficacy relationships around a nonpeptide oxytocin receptor agonist. 2010 , 53, 1546-62	17
827	Toward drug delivery into the brain: synthesis, characterization, and preliminary in vitro assessment of alkylglyceryl-functionalized chitosan nanoparticles. 2010 , 11, 2880-9	18
826	Levodopa delivery systems: advancements in delivery of the gold standard. 2010 , 7, 203-24	20
825	ADME. 2010 , 145-200	3
824	Intrinsic targeting of inflammatory cells in the brain by polyamidoamine dendrimers upon subarachnoid administration. 2010 , 5, 1317-29	88
823	Development of an Efficient Large-Scale Synthesis for a 4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide Derivative for Depression and Anxiety. 2010 , 14, 859-867	11
822	The design of barriers in the hypothalamus allows the median eminence and the arcuate nucleus to enjoy private milieus: the former opens to the portal blood and the latter to the cerebrospinal fluid. 2010 , 31, 757-76	199
821	Candidate anti-A beta fluorene compounds selected from analogs of amyloid imaging agents. 2010 , 31, 1690-9	20
820	Effect of lactoferrin- and transferrin-conjugated polymersomes in brain targeting: in vitro and in vivo evaluations. 2010 , 31, 237-43	47
819	T cell migration into the central nervous system during health and disease: Different molecular keys allow access to different central nervous system compartments. 2010 , 1, 79-93	55
818	Organ distribution of quantum dots after intraperitoneal administration, with special reference to area-specific distribution in the brain. 2010 , 21, 335-103	35
817	Functionalized gold nanoparticles: a detailed in vivo multimodal microscopic brain distribution study. 2010 , 2, 2826-34	96

816	Drug penetration across the blood-brain barrier: an overview. 2010 , 1, 535-62	20
815	Erythropoietin in stroke: quo vadis. 2010 , 10, 937-49	23
814	Various drug delivery approaches to the central nervous system. 2010 , 7, 113-35	29
813	Neurotransplantation of stem cells genetically modified to express human dopamine transporter reduces alcohol consumption. 2010 , 1, 36	3
812	Drug delivery to the CNS and polymeric nanoparticulate carriers. 2010 , 2, 1681-701	13
811	Intranasal delivery of therapeutic proteins for neurological diseases. 2011 , 8, 1277-96	49
810	Preparation of blood-brain barrier-permeable paclitaxel-carrier conjugate and its chemotherapeutic activity in the mouse glioblastoma model. 2011 , 2, 270	14
809	GPR124, an orphan G protein-coupled receptor, is required for CNS-specific vascularization and establishment of the blood-brain barrier. 2011 , 108, 5759-64	136
808	New perspective for the treatment of Alzheimer diseases: liposomal rivastigmine formulations. 2011 , 37, 775-89	53
807	Engineered biological entities for drug delivery and gene therapy protein nanoparticles. 2011 , 104, 247-98	9
806	Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. 2011 , 12, 723-38	1718
805	Fluids and barriers of the CNS establish immune privilege by confining immune surveillance to a two-walled castle moat surrounding the CNS castle. 2011 , 8, 4	144
804	Permeability Barrier. 2011 ,	3
803	In vivo optical imaging of ischemic blood-brain barrier disruption. 2011 , 763, 423-39	18
802	Uptake and permeability studies of BBB-targeting immunoliposomes using the hCMEC/D3 cell line. 2011 , 77, 265-74	92
801	Does VEGF secreted by leukemic cells increase the permeability of blood-brain barrier by disrupting tight-junction proteins in central nervous system leukemia?. 2011 , 76, 618-21	28
800	Transmigration of beta amyloid specific heavy chain antibody fragments across the in vitro blood-brain barrier. 2011 , 190, 37-42	34
799	Advancement in carbon nanotubes: basics, biomedical applications and toxicity. 2011 , 63, 141-63	219

798	Blood-Brain Barrier Permeability: From Bench to Bedside. 2011,	
797	. 2011,	13
796	New Therapeutic Strategies for the Treatment of Brain Tumor. 2011,	
795	N-valproyl-L-tryptophan for CNS-targeting: synthesis, characterization and efficacy in vitro studies of a new potential antiepileptic drug. 2011, 7, 9-17	6
794	Noninvasive, transient and selective blood-brain barrier opening in non-human primates in vivo. 2011, 6, e22598	106
793	Drug Targeting to the Brain - A Review. 2011, 7, 21-36	11
792	Application of NMR spectroscopy in medicinal chemistry and drug discovery. 2011, 11, 93-114	19
791	Enhanced brain targeting of temozolomide in polysorbate-80 coated polybutylcyanoacrylate nanoparticles. 2011, 6, 445-52	93
790	Neurotherapeutic applications of nanoparticles in Alzheimer's disease. 2011, 152, 208-31	144
789	Chloride channel-mediated brain glioma targeting of chlorotoxin-modified doxorubicine-loaded liposomes. 2011, 152, 402-10	96
788	In vitro and in vivo efficacy of edelfosine-loaded lipid nanoparticles against glioma. 2011, 156, 421-6	76
787	Preparation and characterization of liposomal formulations of neurotensin-degrading enzyme inhibitors. 2011, 416, 448-52	6
786	Surface modification of poly(lactide-co-glycolide) nanoparticles by d- α -tocopheryl polyethylene glycol 1000 succinate as potential carrier for the delivery of drugs to the brain. 2011, 392, 335-342	27
785	Supramolecular devices to improve the treatment of brain diseases. <i>Drug Discovery Today</i> , 2011, 16, 3118-24	44
784	Decreased myeloperoxidase expressing cells in the aged rat brain after excitotoxic damage. 2011, 46, 723-30	13
783	The screening toolbox of bioactive substances from natural products: a review. 2011, 82, 1141-51	49
782	Improving the transport of chemotherapeutic drugs across the blood-brain barrier. 2011, 4, 477-90	18
781	Molecular imaging with SPECT as a tool for drug development. 2011, 63, 547-54	67

780	Qualitative prediction of blood-brain barrier permeability on a large and refined dataset. 2011 , 25, 1095-106	67
779	In vivo methods to study uptake of nanoparticles into the brain. 2011 , 28, 456-71	98
778	Lactoferrin conjugated PEG-PLGA nanoparticles for brain delivery: preparation, characterization and efficacy in Parkinson's disease. 2011 , 415, 273-83	178
777	Targeting the brain with PEG-PLGA nanoparticles modified with phage-displayed peptides. 2011 , 32, 4943-50	209
776	Targeting choroid plexus epithelia and ventricular ependyma for drug delivery to the central nervous system. 2011 , 12, 4	19
775	Nanoparticulate devices for brain drug delivery. 2011 , 31, 716-56	47
774	Choline-derivate-modified nanoparticles for brain-targeting gene delivery. 2011 , 23, 4516-20	61
773	Schleuservermittelter Transport von Wirkstoffen ins Gehirn. 2011 , 123, 8148-8165	7
772	Shuttle-mediated drug delivery to the brain. 2011 , 50, 7998-8014	64
771	Design, synthesis and preliminary bio-evaluation of glucose-cholesterol derivatives as ligands for brain targeting liposomes. 2011 , 22, 831-834	14
770	Brain delivery and cellular internalization mechanisms for transferrin conjugated biodegradable polymersomes. 2011 , 415, 284-92	65
769	Blood-brain barrier disruption and vascular damage induced by ultrasound bursts combined with microbubbles can be influenced by choice of anesthesia protocol. 2011 , 37, 1259-70	41
768	Microemulsions and Nanoemulsions for Targeted Drug Delivery to the Brain. 2011 , 7, 119-133	41
767	Exosomes and the blood-brain barrier: implications for neurological diseases. 2011 , 2, 1095-9	80
766	Initial in vivo feasibility of a pre-clinical focused ultrasound system applied to blood-brain barrier opening in monkeys. 2011 ,	0
765	Minimally invasive molecular delivery into the brain using optical modulation of vascular permeability. 2011 , 108, 9256-61	42
764	Prodrugs and endogenous transporters: are they suitable tools for drug targeting into the central nervous system?. 2011 , 17, 3560-76	28
763	Non-invasive optical modulation of local vascular permeability. 2011 ,	1

762	Nanoparticles and toxicity in therapeutic delivery: the ongoing debate. 2011 , 2, 125-32	21
761	Improved outcome of targeted delivery of chemotherapy drugs to the brain using a combined strategy of ultrasound, magnetic targeting and drug-loaded nanoparticles. 2011 , 2, 137-41	5
760	Glia-induced reversible disruption of blood-brain barrier integrity and neuropathological response of the neurovascular unit. 2011 , 39, 172-85	46
759	Brain Delivery of Peptides and Proteins. 2011 , 105-122	3
758	Antibody-conjugated nanoparticles for therapeutic applications. 2012 , 19, 3103-27	83
757	Lipid-based nanocarriers for CNS-targeted drug delivery. 2012 , 7, 71-86	37
756	Targeting accuracy and closing timeline of the microbubble-enhanced focused ultrasound blood-brain barrier opening in non-human primates. 2012 ,	
755	Feasibility study of a single-element transcranial focused ultrasound system for blood-brain barrier opening. 2012 ,	2
754	Real-time, transcranial monitoring of safe blood-brain barrier opening in non-human primates. 2012 ,	0
753	Temporary disruption of the blood-brain barrier by use of ultrasound and microbubbles: safety and efficacy evaluation in rhesus macaques. 2012 , 72, 3652-63	388
752	Glioblastoma multiforme: novel therapeutic approaches. 2012 , 2012, 642345	13
751	Exosomes and the emerging field of exosome-based gene therapy. 2012 , 12, 262-74	136
750	Targeting the brain: advances in drug delivery. 2012 , 13, 2417-26	20
749	Knowledge-Based, Central Nervous System (CNS) Lead Selection and Lead Optimization for CNS Drug Discovery. 2012 , 3, 50-68	267
748	Brain-targeting research of 10-O-nicotinate ginkgolide B: a new prodrug of ginkgolide B. 2012 , 21, 4028-4036	5
747	Phloretin ameliorates 2-chlorohexadecanal-mediated brain microvascular endothelial cell dysfunction in vitro. 2012 , 53, 1770-81	33
746	Drug delivery strategies for the treatment of malignant gliomas. 2012 , 436, 299-310	79
745	Transferrin-conjugated boron nitride nanotubes: protein grafting, characterization, and interaction with human endothelial cells. 2012 , 436, 444-53	41

744	Quantitative proteomics of transporter expression in brain capillary endothelial cells isolated from P-glycoprotein (P-gp), breast cancer resistance protein (Bcrp), and P-gp/Bcrp knockout mice. 2012 , 40, 1164-9	101
743	Nanoparticulate targeted drug delivery using peptides and proteins. 2012 , 236-301	0
742	Selective gelatinase inhibitor neuroprotective agents cross the blood-brain barrier. 2012 , 3, 730-6	25
741	Solanum tuberosum lectin-conjugated PLGA nanoparticles for nose-to-brain delivery: in vivo and in vitro evaluations. 2012 , 20, 174-84	71
740	Designing prodrugs for the treatment of Parkinson's disease. 2012 , 7, 385-406	22
739	Drug-loaded nanocarriers: passive targeting and crossing of biological barriers. 2012 , 19, 3070-102	127
738	Delivery of gold nanoparticles to the brain by conjugation with a peptide that recognizes the transferrin receptor. 2012 , 33, 7194-205	183
737	Diagnostic imaging of Alzheimer's disease with copper and technetium complexes. 2012 , 256, 2367-2380	54
736	Chlorotoxin-modified stealth liposomes encapsulating levodopa for the targeting delivery against Parkinson's disease in the MPTP-induced mice model. 2012 , 20, 67-75	52
735	In vivo assessment of the permeability of the blood-brain barrier and blood-retinal barrier to fluorescent indoline derivatives in zebrafish. 2012 , 13, 101	32
734	β-cyclodextrin-poly(ε-amino ester) nanoparticles for sustained drug delivery across the blood-brain barrier. 2012 , 13, 3533-41	57
733	CHAPTER 18: Medicinal Chemistry Challenges in CNS Drug Discovery. 2012 , 465-509	5
732	In-vitro evaluation of the P-glycoprotein interactions of a series of potentially CNS-active Amaryllidaceae alkaloids. 2012 , 64, 1667-77	13
731	CHAPTER 17: Crossing the Blood-brain Barrier [Methods for Evaluating CNS Exposure. 2012 , 445-464	1
730	Challenges in drug delivery to the brain: nature is against us. 2012 , 164, 145-55	106
729	Ultrasound-mediated blood-brain/blood-tumor barrier disruption improves outcomes with trastuzumab in a breast cancer brain metastasis model. 2012 , 163, 277-84	152
728	Establishment of a new conditionally immortalized cell line from human brain microvascular endothelial cells: a promising tool for human blood-brain barrier studies. 2012 , 1488, 113-22	34
727	Low-frequency ultrasound irradiation increases blood-tumor barrier permeability by transcellular pathway in a rat glioma model. 2012 , 48, 281-90	22

726	Inhibition of monoamine oxidase by derivatives of piperine, an alkaloid from the pepper plant <i>Piper nigrum</i> , for possible use in Parkinson's disease. 2012 , 22, 7183-8	38
725	In vitro models of the blood-brain barrier. 2012 , 814, 431-49	12
724	Chemical optimization of new ligands of the low-density lipoprotein receptor as potential vectors for central nervous system targeting. 2012 , 55, 2227-41	53
723	Magnesium in edema and blood-brain barrier disruption. 135-144	3
722	Nanowired drug delivery to enhance neuroprotection in spinal cord injury. 2012 , 11, 86-95	31
721	Intracellular delivery mechanism and brain delivery kinetics of biodegradable cationic bovine serum albumin-conjugated polymersomes. 2012 , 7, 3421-32	14
720	Discovery of cyclic sulfone hydroxyethylamines as potent and selective β -site APP-cleaving enzyme 1 (BACE1) inhibitors: structure-based design and in vivo reduction of amyloid β -peptides. 2012 , 55, 3364-86	83
719	A Bayesian approach to in silico blood-brain barrier penetration modeling. 2012 , 52, 1686-97	74
718	Multifunctionalized CMChT/PAMAM dendrimer nanoparticles modulate the cellular uptake by astrocytes and oligodendrocytes in primary cultures of glial cells. 2012 , 12, 591-7	28
717	Nanostructure-based drug delivery systems for brain targeting. 2012 , 38, 387-411	40
716	Peptide-Mediated BloodBrain Barrier Transport of Polymersomes. 2012 , 124, 8464-8467	10
715	Peptide-mediated blood-brain barrier transport of polymersomes. 2012 , 51, 8339-42	87
714	Polycyclic cage structures as lipophilic scaffolds for neuroactive drugs. 2012 , 7, 375-84	53
713	Novel models for assessing blood-brain barrier drug permeation. 2012 , 8, 647-53	31
712	Strategies for delivery of therapeutics into the central nervous system for treatment of lysosomal storage disorders. 2012 , 2, 169-86	30
711	Prodrug approaches to reduce hyperexcitation in the CNS. 2012 , 64, 666-85	10
710	The transport of antiepileptic drugs by P-glycoprotein. 2012 , 64, 930-42	155
709	Interactions between antidepressants and P-glycoprotein at the blood-brain barrier: clinical significance of in vitro and in vivo findings. 2012 , 165, 289-312	135

708	Peptide therapeutics for CNS indications. 2012 , 83, 559-66	69
707	Tight junction in blood-brain barrier: an overview of structure, regulation, and regulator substances. 2012 , 18, 609-15	166
706	Cholesteryl-functionalized ADNF-9 peptide: enhanced membrane transport through mouse neuroblastoma Neuro-2a cells. 2012 , 80, 148-54	
705	Therapeutics, imaging and toxicity of nanomaterials in the central nervous system. 2012 , 161, 290-306	58
704	Prediction of polar surface area of drug molecules: a QSPR approach. 2013 , 5, 222-7	3
703	Medicinal chemistry based approaches and nanotechnology-based systems to improve CNS drug targeting and delivery. 2013 , 33, 457-516	56
702	The mastermind approach to CNS drug therapy: translational prediction of human brain distribution, target site kinetics, and therapeutic effects. 2013 , 10, 12	79
701	Drug delivery across the blood-brain barrier. 2013 , 10, 1471-2	20
700	Transferrin-conjugated, fluorescein-loaded magnetic nanoparticles for targeted delivery across the blood-brain barrier. 2013 , 24, 2371-9	51
699	Emerging mass spectrometry-based approaches to probe protein-receptor interactions: focus on overcoming physiological barriers. 2013 , 65, 1020-30	7
698	Clinical pharmacokinetics of antibacterials in cerebrospinal fluid. 2013 , 52, 511-42	27
697	O-phenyl carbamate and phenyl urea thiiranes as selective matrix metalloproteinase-2 inhibitors that cross the blood-brain barrier. 2013 , 56, 8139-50	30
696	Virtual screening and structure-based discovery of indole acylguanidines as potent β -secretase (BACE1) inhibitors. 2013 , 18, 5706-22	17
695	Multiple treatments with liposomal doxorubicin and ultrasound-induced disruption of blood-tumor and blood-brain barriers improve outcomes in a rat glioma model. 2013 , 169, 103-11	171
694	Molecular imaging of drug transit through the blood-brain barrier with MALDI mass spectrometry imaging. 2013 , 3, 2859	99
693	Bioimpact of Carbon Nanomaterials. 2013 , 193-271	4
692	Liposomes modified with P-aminophenyl- β -D-mannopyranoside: a carrier for targeting cerebral functional regions in mice. 2013 , 84, 505-16	32
691	Paclitaxel-hyaluronic nanoconjugates prolong overall survival in a preclinical brain metastases of breast cancer model. 2013 , 12, 2389-99	66

690	The role of hypothalamic H1 receptor antagonism in antipsychotic-induced weight gain. 2013 , 27, 423-34	66
689	Nanoparticulate flurbiprofen reduces amyloid- β 2 generation in an in vitro blood-brain barrier model. 2013 , 5, 51	42
688	Nanoparticle accumulation and transcytosis in brain endothelial cell layers. 2013 , 5, 11153-65	90
687	Immunoliposomes for Alzheimer's disease therapy. 2013 ,	1
686	The promiscuous binding of pharmaceutical drugs and their transporter-mediated uptake into cells: what we (need to) know and how we can do so. <i>Drug Discovery Today</i> , 2013 , 18, 218-39	8.8 120
685	Preparation and evaluation of BBB-permeable trehalose derivatives as potential therapeutic agents for Huntington's disease. 2013 , 4, 310-316	13
684	Bacopa monniera stabilized gold nanoparticles (BmGNPs) alleviated the oxidative stress induced by aluminum in albino mice. 2013 , 5, 113-118	9
683	Serotonin transporter protein (SERT) and P-glycoprotein (P-gp) binding activity of montanine and coccinine from three species of <i>Haemanthus</i> L. (Amaryllidaceae). 2013 , 88, 101-106	8
682	Secreted luciferase for in vivo evaluation of systemic protein delivery in mice. 2013 , 53, 63-73	15
681	Anti-hyperalgesic activity of corilagin, a tannin isolated from <i>Phyllanthus niruri</i> L. (Euphorbiaceae). 2013 , 146, 318-23	54
680	Liposomes for brain delivery. 2013 , 10, 1003-22	72
679	Radio electric conveyed fields directly reprogram human dermal skin fibroblasts toward cardiac, neuronal, and skeletal muscle-like lineages. 2013 , 22, 1227-35	51
678	Transporters in Anti-Parasitic Drug Development and Resistance. 2013 , 335-349	5
677	Innovative therapeutic strategies in the treatment of brain metastases. 2013 , 14, 2135-74	34
676	Up-regulating blood brain barrier permeability of nanoparticles via multivalent effect. 2013 , 30, 2538-48	31
675	Optimization of brain targeted chitosan nanoparticles of Rivastigmine for improved efficacy and safety. 2013 , 59, 72-83	64
674	Glial-cell-mediated re-induction of the blood-brain barrier phenotype in brain capillary endothelial cells: a differential gel electrophoresis study. 2013 , 13, 1185-99	17
673	Peroxisome proliferator-activated receptors and Alzheimer's disease: hitting the blood-brain barrier. 2013 , 48, 438-51	33

672	Brain-reactive antibodies and disease. 2013 , 31, 345-85	97
671	Designing drugs with multi-target activity: the next step in the treatment of neurodegenerative disorders. 2013 , 8, 115-29	43
670	Opening of the blood-brain barrier with an unfocused ultrasound device in rabbits. 2013 , 119, 887-98	39
669	The BloodBrain Barrier: An Introduction to Its Structure and Function. 2013 , 1-20	2
668	P-glycoprotein mediated efflux limits substrate and drug uptake in a preclinical brain metastases of breast cancer model. 2013 , 4, 136	41
667	Increased nanoparticle-loaded exogenous macrophage migration into the brain following PDT-induced blood-brain barrier disruption. 2013 , 45, 524-32	34
666	Which drug or drug delivery system can change clinical practice for brain tumor therapy?. 2013 , 15, 656-69	32
665	Blood-brain barrier dysfunction after primary blast injury in vitro. 2013 , 30, 1652-63	50
664	Engineering a lysosomal enzyme with a derivative of receptor-binding domain of apoE enables delivery across the blood-brain barrier. 2013 , 110, 2999-3004	109
663	Transport of Nanoparticles across BloodBrain Barrier. 2013 , 163-174	
662	Bio-Functional Polymer Vesicles for Applications in Nanomedicine. 2013 , 481-503	
661	Formulations for Intranasal Delivery of Pharmacological Agents to Combat Brain Disease: A New Opportunity to Tackle GBM?. 2013 , 5, 1020-48	103
660	Evaluation of brain targeting and mucosal integrity of nasally administrated nanostructured carriers of a CNS active drug, clonazepam. 2013 , 16, 456-69	14
659	Targeted brain derived neurotropic factors (BDNF) delivery across the blood-brain barrier for neuro-protection using magnetic nano carriers: an in-vitro study. 2013 , 8, e62241	95
658	Rationally designed multi-targeted agents against neurodegenerative diseases. 2013 , 20, 1662-72	70
657	Nanotechnology and Brain Tumors Drug Delivery. 2013 , 3, 26-36	4
656	Polymer Nanoparticles for Smart Drug Delivery. 2014 ,	47
655	Real-time, transcranial monitoring of safe blood-brain barrier opening in non-human primates. 2014 , 9, e84310	62

654	Formulation and delivery of itraconazole to the brain using a nanolipid carrier system. 2014 , 9, 2117-26	58
653	Recovery from ICH [Potential Targets. 2014 ,	
652	Multifunctional targeting daunorubicin plus quinacrine liposomes, modified by wheat germ agglutinin and tamoxifen, for treating brain glioma and glioma stem cells. 2014 , 5, 6497-511	46
651	Lysosomes and Nanotherapeutics: Diseases, Treatments, and Side Effects. 2014 , 261-305	2
650	Synthesis of a Clickable Angiopep-conjugated p-coumaric acid for brain-targeted delivery. 2014 , 49, 8204-8213	3
649	Cellular Mechanisms in Nanomaterial Internalization, Intracellular Trafficking, and Toxicity. 2014 , 201-227	16
648	How drugs get into cells: tested and testable predictions to help discriminate between transporter-mediated uptake and lipoidal bilayer diffusion. 2014 , 5, 231	114
647	Pharmaceutical Nanotechnology: Overcoming Drug Delivery Challenges in Contemporary Medicine. 2014 , 191-236	
646	Novel treatment strategies for brain tumors and metastases. 2014 , 3, 279-96	14
645	Scopine as a novel brain-targeting moiety enhances the brain uptake of chlorambucil. 2014 , 25, 2046-54	10
644	'à la carte' peptide shuttles: tools to increase their passage across the blood-brain barrier. 2014 , 9, 1594-601	16
643	Applications of dendrimers for brain delivery and cancer therapy. 2014 , 9, 2403-14	48
642	Nanomedicine. 2014 ,	14
641	Normalization and improvement of CNS deficits in mice with Hurler syndrome after long-term peripheral delivery of BBB-targeted iduronidase. 2014 , 22, 2028-2037	15
640	Optically enhanced blood-brain-barrier crossing of plasmonic-active nanoparticles in preclinical brain tumor animal models. 2014 ,	2
639	Assessing the transport of receptor-mediated drug-delivery devices across cellular monolayers. 2014 , 25, 455-73	1
638	Brain drug-delivery attempts. 2014 , 35-52	
637	Synthesis and characterisation of poly(lactide-co-glycolide) nanospheres using vitamin E emulsifier prepared through one-step oil-in-water emulsion and solvent evaporation techniques. 2014 , 8, 257-62	7

636	Use of Genetically Altered Stem Cells for the Treatment of Huntington's Disease. 2014 , 4, 202-19	10
635	Rhenium and technetium based radiopharmaceuticals: Development and recent advances. 2014 , 751, 83-89	74
634	Haloperidol-loaded intranasally administered lectin functionalized poly(ethylene glycol)-block-poly(D,L)-lactic-co-glycolic acid (PEG-PLGA) nanoparticles for the treatment of schizophrenia. 2014 , 87, 30-9	54
633	Polymersomes conjugated with des-octanoyl ghrelin for the delivery of therapeutic and imaging agents into brain tissues. 2014 , 35, 2051-65	16
632	Ultrasound-mediated blood-brain barrier disruption for targeted drug delivery in the central nervous system. 2014 , 72, 94-109	253
631	Implantable controlled release devices for BMP-7 delivery and suppression of glioblastoma initiating cells. 2014 , 35, 2859-67	31
630	Breaking and entering into the CNS: clues from solid tumor and nonmalignant models with relevance to hematopoietic malignancies. 2014 , 31, 257-67	8
629	Efficacy of Cisplatin-loaded polybutyl cyanoacrylate nanoparticles on the glioblastoma. 2014 , 35, 4799-806	35
628	Peptide-Based Delivery of Oligonucleotides Across BloodBrain Barrier Model. 2014 , 20, 169-178	17
627	Pharmacokinetics and metabolism of 4-O-methylhonokiol in rats. 2014 , 28, 568-78	12
626	Overcoming the blood-brain barrier in chemotherapy treatment of pediatric brain tumors. 2014 , 31, 531-40	17
625	Specific binding, uptake, and transport of ICAM-1-targeted nanocarriers across endothelial and subendothelial cell components of the blood-brain barrier. 2014 , 31, 1855-66	30
624	Novel central nervous system drug delivery systems. 2014 , 83, 507-20	75
623	Calixarene-Mediated Liquid-Membrane Transport of Choline Conjugates. 2014 , 2014, 2972-2979	13
622	Engineering of chimeric catalase-Angiopep-2 for intracellular protection of brain endothelial cells against oxidative stress. 2014 , 68, 60-6	7
621	Cell penetrating peptides: efficient vectors for delivery of nanoparticles, nanocarriers, therapeutic and diagnostic molecules. 2014 , 57, 78-94	197
620	Imaging approach to mechanistic study of nanoparticle interactions with the blood-brain barrier. 2014 , 8, 4304-12	97
619	Nanotherapeutic approaches for brain cancer management. 2014 , 10, 905-19	70

618	Nanotoxicology. 2014,	14
617	Smart nanodevice combined tumor-specific vector with cellular microenvironment-triggered property for highly effective antiglioma therapy. 2014, 8, 1191-203	67
616	Magnetic resonance-guided focused ultrasound: a new technology for clinical neurosciences. 2014, 32, 253-69	36
615	Data-driven medicinal chemistry in the era of big data. <i>Drug Discovery Today</i> , 2014, 19, 859-68	8.8 101
614	Combinatorial peptide libraries: mining for cell-binding peptides. 2014, 114, 1020-81	156
613	Ligands for glaucoma-associated myocilin discovered by a generic binding assay. 2014, 9, 517-25	12
612	Methyl Yellow: A Potential Drug Scaffold for Parkinson's Disease. 2014, 15, 1591-1598	7
611	Paracrine signalling of inflammatory cytokines from an in vitro blood brain barrier model upon exposure to polymeric nanoparticles. 2014, 139, 923-30	32
610	Biocompatible, hyperbranched nanocarriers for the transport and release of copper ions. 2014, 2, 3915-3918	16
609	Platelet activating factor induces transient blood-brain barrier opening to facilitate edaravone penetration into the brain. 2014, 128, 662-71	14
608	Engineering and pharmacology of blood-brain barrier-permeable bispecific antibodies. 2014, 71, 301-35	44
607	Copper transport mediated by nanocarrier systems in a blood-brain barrier in vitro model. 2014, 15, 1910-9	9
606	Cell-culture models of the blood-brain barrier. 2014, 45, 2514-26	101
605	Physiology and Pathophysiology of Cerebral Microcirculation. 2014, 1-31	
604	Reversible dimers of the atypical antipsychotic quetiapine inhibit p-glycoprotein-mediated efflux in vitro with increased binding affinity and in situ at the blood-brain barrier. 2014, 5, 305-17	21
603	A randomized crossover, pilot study examining the effects of a normal protein vs. high protein breakfast on food cravings and reward signals in overweight/obese "breakfast skipping", late-adolescent girls. 2014, 13, 80	28
602	OX26/CTX-conjugated PEGylated liposome as a dual-targeting gene delivery system for brain glioma. 2014, 13, 191	54
601	Intra-arterial carboplatin as a salvage strategy in the treatment of recurrent glioblastoma multiforme. 2014, 119, 397-403	15

600	Multifunctional liposomes loaded with paclitaxel and artemether for treatment of invasive brain glioma. 2014 , 35, 5591-604		129
599	Multidrug resistance in cancer or inefficacy of neuroactive agents: innovative strategies to inhibit or circumvent the active efflux transporters selectively. <i>Drug Discovery Today</i> , 2014 , 19, 1563-71	8.8	23
598	Imaging and histological characterization of a human brain xenograft in pig: the first induced glioma model in a large animal. 2014 , 221, 159-65		15
597	Glucose transporter and folic acid receptor-mediated Pluronic P105 polymeric micelles loaded with doxorubicin for brain tumor treating. 2014 , 22, 712-23		40
596	Sulforaphane alleviates scopolamine-induced memory impairment in mice. 2014 , 85, 23-32		53
595	Development and characterization of functionalized niosomes for brain targeting of dynorphin-B. 2014 , 87, 73-9		56
594	Nanoparticles of 2-deoxy-D-glucose functionalized poly(ethylene glycol)-co-poly(trimethylene carbonate) for dual-targeted drug delivery in glioma treatment. 2014 , 35, 518-29		184
593	Evaluation of P-glycoprotein (abcb1a/b) modulation of [(18)F]fallypride in MicroPET imaging studies. 2014 , 84, 152-8		9
592	Intrathecal delivery of protein therapeutics to the brain: a critical reassessment. 2014 , 144, 114-22		99
591	Prolonged survival upon ultrasound-enhanced doxorubicin delivery in two syngenic glioblastoma mouse models. 2014 , 187, 74-82		76
590	Surface functionalisation regulates polyamidoamine dendrimer toxicity on blood-brain barrier cells and the modulation of key inflammatory receptors on microglia. 2014 , 8, 158-68		27
589	Isolation of primary murine brain microvascular endothelial cells. 2014 , e52204		48
588	RNAi Nanomedicines toward Advancing Personalized Medicine: Challenges and Opportunities for Targeted Therapy in the Immune System. 2014 , 97-118		
587	Modulation of intercellular junctions by cyclic-ADT peptides as a method to reversibly increase blood-brain barrier permeability. 2015 , 104, 1065-75		32
586	Designing CNS Drugs for Optimal Brain Exposure. 2015 , 385-424		2
585	Advances in Non-Invasive Drug Delivery to the Brain. 2015 ,		
584	LRP-1-mediated intracellular antibody delivery to the Central Nervous System. 2015 , 5, 11990		95
583	The Expression and Function of ABC Transporters at the Blood-Brain Barrier. 2015 , 172-214		

582	Neuronal-Glial-Endothelial Interactions Regulate Central Nervous System Homeostasis. 2015 , 36-75	
581	A new liquid chromatography-mass spectrometry-based method to quantitate exogenous recombinant transferrin in cerebrospinal fluid: a potential approach for pharmacokinetic studies of transferrin-based therapeutics in the central nervous systems. 2015 , 21, 369-76	2
580	Prodrug strategies for brain delivery. 2015 , 144-156	1
579	Purification of Mouse Brain Vessels. 2015 , e53208	39
578	Withdrawn: OCTN2-mediated active targeting L-carnitine modified PLGA based nanoparticles for enhanced oral paclitaxel delivery. 2015 ,	
577	Effect of avermectin (AVM) on the expression of γ -aminobutyric acid A receptor (GABAAR) in <i>Carassius gibelio</i> (Bloch, 1782). 2015 , 31, 862-869	1
576	NKTR-102 Efficacy versus irinotecan in a mouse model of brain metastases of breast cancer. 2015 , 15, 685	30
575	The blood-brain barrier and nasal drug delivery to the central nervous system. 2015 , 29, 124-7	62
574	Interaction between therapeutic interventions for Alzheimer's disease and physiological A β clearance mechanisms. 2015 , 7, 64	19
573	Ultrasound effects on brain-targeting mannosylated liposomes: in vitro and blood-brain barrier transport investigations. 2015 , 9, 3885-98	8
572	Sustained-release nanoART formulation for the treatment of neuroAIDS. 2015 , 10, 1077-93	77
571	Peptide gH625 enters into neuron and astrocyte cell lines and crosses the blood-brain barrier in rats. 2015 , 10, 1885-98	27
570	Neurotransmitters as food supplements: the effects of GABA on brain and behavior. 2015 , 6, 1520	132
569	Ligand-Appended BBB-Targeted Nanocarriers (LABTNs). 2015 , 32, 149-80	27
568	. 2015 ,	6
567	Neuropeptides I: classification, synthesis and co-localization with classical neurotransmitters. 257-285	
566	Nasal Drug Delivery: A Potential Route for Brain Targetting. 2015 , 1, 65	3
565	Analysis of Physicochemical Properties for Drugs of Natural Origin. 2015 , 78, 1370-82	50

564	Parthenolide prodrug LC-1 slows growth of intracranial glioma. 2015 , 25, 2493-5	14
563	Lipid bilayer crossing--the gate of symmetry. Water-soluble phenylproline-based blood-brain barrier shuttles. 2015 , 137, 7357-64	36
562	Blood-brain barrier-permeable fluorone-labeled dieckmols acting as neuronal ER stress signaling inhibitors. 2015 , 61, 52-60	17
561	Brain-derived neurotrophic factor (BDNF) as a potential mechanism of the effects of acute exercise on cognitive performance. 2015 , 4, 14-23	104
560	An Increase in Plasma Homovanillic Acid with Cocoa Extract Consumption Is Associated with the Alleviation of Depressive Symptoms in Overweight or Obese Adults on an Energy Restricted Diet in a Randomized Controlled Trial. 2015 , 146, 8975-9045	19
559	Theranostic USPIO-Loaded Microbubbles for Mediating and Monitoring Blood-Brain Barrier Permeation. 2015 , 25, 36-43	97
558	Lactoferrin- and antitransferrin-modified liposomes for brain targeting of the NK3 receptor agonist senktide: preparation and in vivo evaluation. 2015 , 479, 129-37	40
557	A polyphenylene dendrimer drug transporter with precisely positioned amphiphilic surface patches. 2015 , 4, 377-84	22
556	Cerebral Microcirculation: An Introduction. 2015 , 655-680	1
555	Exosome delivered anticancer drugs across the blood-brain barrier for brain cancer therapy in Danio rerio. 2015 , 32, 2003-14	539
554	Qualitative and quantitative structure-activity relationship modelling for predicting blood-brain barrier permeability of structurally diverse chemicals. 2015 , 26, 95-124	15
553	Intranasal and intravenous administration of octa-arginine modified poly(lactic-co-glycolic acid) nanoparticles facilitates central nervous system delivery of loperamide. 2015 , 67, 525-36	21
552	Drug access to the central nervous system in Alzheimer's disease: preclinical and clinical insights. 2015 , 32, 819-39	27
551	A convenient method for hTfR1 inclusion body purification. 2015 , 45, 743-53	2
550	Permeability of the Blood-Brain Barrier: Molecular Mechanism of Transport of Drugs and Physiologically Important Compounds. 2015 , 248, 651-69	62
549	Plasmonic gold nanostars for multi-modality sensing and diagnostics. 2015 , 15, 3706-20	50
548	Decreased affinity for efflux transporters increases brain penetrance and molecular targeting of a PI3K/mTOR inhibitor in a mouse model of glioblastoma. 2015 , 17, 1210-9	21
547	7,8-Dihydroxyflavone as a pro-neurotrophic treatment for neurodevelopmental disorders. 2015 , 89, 170-80	29

546	Recent prospective of surface engineered Nanoparticles in the management of Neurodegenerative disorders. 2016 , 44, 780-91	7
545	Nanoneurotherapeutics approach intended for direct nose to brain delivery. 2015 , 41, 1922-34	40
544	Mechanism of brain targeting by dexibuprofen prodrugs modified with ethanolamine-related structures. 2015 , 35, 1985-94	10
543	A novel LDL-mimic nanocarrier for the targeted delivery of curcumin into the brain to treat Alzheimer's disease. 2015 , 134, 88-97	104
542	Intriguing possibilities and beneficial aspects of transporter-conscious drug design. 2015 , 23, 4119-4131	18
541	Targeted Brain Delivery of Bioactive Molecules Using Nanocarriers. 2015 , 07,	5
540	Calixarene-Mediated Liquid Membrane Transport of Choline Conjugates 2: Transport of Drug-Choline Conjugates and Neurotransmitters. 2015 , 2015, 2683-2690	6
539	Protective effects of low-intensity pulsed ultrasound on aluminum-induced cerebral damage in Alzheimer's disease rat model. 2015 , 5, 9671	81
538	Hydrocortisone enhances the barrier properties of HBMEC/ci1a brain microvascular endothelial cell line, through mesenchymal-to-endothelial transition-like effects. 2015 , 12, 7	24
537	Nanoparticle-mediated growth factor delivery systems: A new way to treat Alzheimer's disease. 2015 , 206, 187-205	52
536	Antisense oligonucleotides in therapy for neurodegenerative disorders. 2015 , 87, 90-103	205
535	Nanoemulsion in Drug Targeting. 2015 , 433-459	6
534	Novel flow cytometric analysis of the blood-brain barrier. 2015 , 87, 897-907	3
533	Drug Delivery to the Brain via Focused Ultrasound. 2015 , 441-474	2
532	Enhancement in blood-tumor barrier permeability and delivery of liposomal doxorubicin using focused ultrasound and microbubbles: evaluation during tumor progression in a rat glioma model. 2015 , 60, 2511-27	63
531	Multiple sessions of liposomal doxorubicin delivery via focused ultrasound mediated blood-brain barrier disruption: a safety study. 2015 , 204, 60-9	83
530	p-Aminophenyl- β -D-mannopyranoside engineered lipidic nanoparticles for effective delivery of docetaxel to brain. 2015 , 188, 1-9	34
529	Neuronal and vascular interactions. 2015 , 38, 25-46	126

528	Targeting therapeutics across the blood brain barrier (BBB), prerequisite towards thrombolytic therapy for cerebrovascular disorders-an overview and advancements. 2015 , 16, 223-33	39
527	Current strategies for targeted delivery of bio-active drug molecules in the treatment of brain tumor. 2015 , 23, 865-87	51
526	Gene delivery to the spinal cord using MRI-guided focused ultrasound. 2015 , 22, 568-77	51
525	Nano-enabled delivery of diverse payloads across complex biological barriers. 2015 , 219, 548-559	41
524	Molecular determinants of blood-brain barrier permeation. 2015 , 6, 961-71	53
523	A simple and versatile method for microencapsulation of anti-epileptic drugs for focal therapy of epilepsy. 2015 , 3, 7255-7261	6
522	Tissue Non-specific Alkaline Phosphatase (TNAP) in Vessels of the Brain. 2015 , 76, 125-51	16
521	Protective spin-labeled fluorenes maintain amyloid beta peptide in small oligomers and limit transitions in secondary structure. 2015 , 1854, 1860-1870	6
520	Determination of an optimal dosing schedule for combining Irinophore C and temozolomide in an orthotopic model of glioblastoma. 2015 , 220, 348-357	15
519	Docosahexaenoic acid attenuates hyperglycemia-enhanced hemorrhagic transformation after transient focal cerebral ischemia in rats. 2015 , 301, 471-9	9
518	New horizons in therapeutic antibody discovery: opportunities and challenges versus small-molecule therapeutics. 2015 , 20, 437-53	35
517	CNS drug design: balancing physicochemical properties for optimal brain exposure. 2015 , 58, 2584-608	318
516	Open challenges in magnetic drug targeting. 2015 , 7, 446-57	89
515	Mössbauer study of exogenous iron redistribution between the brain and the liver after administration of $^{57}\text{Fe}_3\text{O}_4$ ferrofluid in the ventricle of the rat brain. 2015 , 380, 78-84	9
514	Brain-targeted delivery of doxorubicin using glutathione-coated nanoparticles for brain cancers. 2015 , 20, 497-506	37
513	Targeting receptor-mediated transport for delivery of biologics across the blood-brain barrier. 2015 , 55, 613-31	199
512	Functionalized nanoscale micelles with brain targeting ability and intercellular microenvironment biosensitivity for anti-intracranial infection applications. 2015 , 4, 291-300	33
511	Nanobiomaterials set to revolutionize drug-delivery systems for the treatment of diabetes: State-of-the-art. 2016 , 487-514	3

510	Destruction of vasculogenic mimicry channels by targeting epirubicin plus celecoxib liposomes in treatment of brain glioma. 2016 , 11, 1131-46	21
509	Are the changes in the peripheral brain-derived neurotrophic factor levels due to platelet activation?. 2016 , 6, 84-101	76
508	Evolving Drug Delivery Strategies to Overcome the Blood Brain Barrier. 2016 , 22, 1177-1193	167
507	Nanomedicine in Central Nervous System (CNS) Disorders: A Present and Future Prospective. 2016 , 6, 319-335	53
506	7,8-Dihydroxyflavone Ameliorates Cognitive Impairment by Inhibiting Expression of Tau Pathology in ApoE-Knockout Mice. 2016 , 8, 287	11
505	Targeted Doxorubicin Delivery to Brain Tumors via Minicells: Proof of Principle Using Dogs with Spontaneously Occurring Tumors as a Model. 2016 , 11, e0151832	47
504	Getting into the brain: liposome-based strategies for effective drug delivery across the blood-brain barrier. 2016 , 11, 5381-5414	204
503	Development of TIMP1 magnetic nanoformulation for regulation of synaptic plasticity in HIV-1 infection. 2016 , 11, 4287-98	15
502	Optimizing superparamagnetic iron oxide nanoparticles as drug carriers using an in vitro blood-brain barrier model. 2016 , 11, 5371-5379	30
501	Transcytosis-Targeting Peptide: A Conductor of Liposomal Nanoparticles through the Endothelial Cell Barrier. 2016 , 12, 1212-21	8
500	Bioactive Nanomaterials for Neural Engineering. 2016 , 181-206	1
499	Permeability of blood-brain barrier in macaque model of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson disease. 2016 , 70, 231-9	9
498	Neural Engineering. 2016 ,	6
497	An Unexpected Transient Breakdown of the Blood Brain Barrier Triggers Passage of Large Intravenously Administered Nanoparticles. 2016 , 6, 22595	28
496	BDNF Responses in Healthy Older Persons to 35 Minutes of Physical Exercise, Cognitive Training, and Mindfulness: Associations with Working Memory Function. 2017 , 55, 645-657	85
495	Challenges in the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer with brain metastases. 2016 , 35, 323-32	9
494	In vitro and in vivo brain-targeting chemo-photothermal therapy using graphene oxide conjugated with transferrin for Gliomas. 2016 , 31, 1123-31	29
493	Comparison of Linear and Cyclic His-Ala-Val Peptides in Modulating the Blood-Brain Barrier Permeability: Impact on Delivery of Molecules to the Brain. 2016 , 105, 797-807	25

492	Design and evaluation of lipoprotein resembling curcumin-encapsulated protein-free nanostructured lipid carrier for brain targeting. 2016 , 506, 46-56	31
491	In silico pathway analysis of MAPKs and computational investigation of bipyrazole analogues as novel p38alpha MAPK inhibitors. 2016 , 12, 1	0
490	A library of AuNPs modified by RAFT polymers of different charge and chain length: high throughput synthesis and synchrotron XFM imaging using a zebrafish larvae model. 2016 , 6, 23550-23563	6
489	Cell Culture Models for Drug Transport Studies. 2016 , 131-151	2
488	The Blood-Brain Barrier and the Design of New Antiepileptic Drugs. 2016 , 221-236	
487	Nanotechnology and Its Drug Delivery Applications. 2016 , 1-32	4
486	Pathways for Drug Delivery to the Central Nervous System. 2016 , 353-382	3
485	Natural Polymer Drug Delivery Systems. 2016 ,	69
484	The Cerebral Circulation, Second Edition. 2016 , 8, 1-80	5
483	Growth inhibition in a brain metastasis model by antibody delivery using focused ultrasound-mediated blood-brain barrier disruption. 2016 , 238, 281-288	69
482	The Potential of Gonadal Hormone Signalling Pathways as Therapeutics for Dementia. 2016 , 60, 336-348	5
481	The Effects of Acute Exercise on Memory and Brain-Derived Neurotrophic Factor (BDNF). 2016 , 38, 331-340	69
480	A novel PEG-haloperidol conjugate with a non-degradable linker shows the feasibility of using polymer-drug conjugates in a non-prodrug fashion. 2016 , 7, 7204-7210	8
479	Ultrasound-mediated drug delivery to the brain: principles, progress and prospects. 2016 , 20, 41-48	80
478	Localized Down-regulation of P-glycoprotein by Focused Ultrasound and Microbubbles induced Blood-Brain Barrier Disruption in Rat Brain. 2016 , 6, 31201	54
477	Pharmacological considerations for predicting PK/PD at the site of action for therapeutic proteins. 2016 , 21-22, 35-39	5
476	Development of a Method and Validation for the Quantitation of FruArg in Mice Plasma and Brain Tissue Using UPLC-MS/MS. 2016 , 1, 663-668	5
475	Nanomedicine as a non-invasive strategy for drug delivery across the blood brain barrier. 2016 , 515, 331-342	54

474	Magnetically guided central nervous system delivery and toxicity evaluation of magneto-electric nanocarriers. 2016 , 6, 25309	69
473	Liposome-Based Systemic Glioma-Targeted Drug Delivery Enabled by All-d Peptides. 2016 , 8, 29977-29985	55
472	Progress and perspectives on targeting nanoparticles for brain drug delivery. 2016 , 6, 268-86	291
471	Development of Passive Immunotherapies for Synucleinopathies. 2016 , 31, 203-13	66
470	In Vitro screening of nanomedicines through the blood brain barrier: A critical review. 2016 , 103, 229-255	36
469	Targeted gene transfer to the brain via the delivery of brain-penetrating DNA nanoparticles with focused ultrasound. 2016 , 223, 109-117	104
468	P-glycoprotein differentially affects escitalopram, levomilnacipran, vilazodone and vortioxetine transport at the mouse blood-brain barrier in vivo. 2016 , 103, 104-11	18
467	Review on photoacoustic imaging of the brain using nanoprobes. 2016 , 3, 010901	68
466	Antibody Approaches To Treat Brain Diseases. 2016 , 34, 36-48	46
465	Brain-targeted co-delivery of therapeutic gene and peptide by multifunctional nanoparticles in Alzheimer's disease mice. 2016 , 80, 33-45	108
464	Synthesis and characterization of brain penetrant prodrug of neuroprotective D-264: Potential therapeutic application in the treatment of Parkinson's disease. 2016 , 103, 62-70	5
463	Quantitative analysis of nanoparticle transport through in vitro blood-brain barrier models. 2016 , 4, e1143545	10
462	Role of scavenger receptors in peptide-based delivery of plasmid DNA across a blood-brain barrier model. 2016 , 500, 128-35	25
461	Development of siRNA-loaded chitosan nanoparticles targeting Galectin-1 for the treatment of glioblastoma multiforme via intranasal administration. 2016 , 227, 71-81	90
460	Focused ultrasound to transiently disrupt the blood brain barrier. 2016 , 28, 187-9	4
459	Review of Neuromodulation Techniques and Technological Limitations. 2016 , 33, 368-377	8
458	Ultrasound-induced opening of the blood-brain barrier to enhance temozolomide and irinotecan delivery: an experimental study in rabbits. 2016 , 124, 1602-10	40
457	Functionalized nanocarrier combined seizure-specific vector with P-glycoprotein modulation property for antiepileptic drug delivery. 2016 , 74, 64-76	28

456	Brain-blood ratio: implications in brain drug delivery. 2016 , 13, 85-92	33
455	MRI contrast agent for targeting glioma: interleukin-13 labeled liposome encapsulating gadolinium-DTPA. 2016 , 18, 691-9	33
454	Particulate formulations based on chitosan for nose-to-brain delivery of drugs. A review. 2016 , 32, 77-87	51
453	Glucose Transporters at the Blood-Brain Barrier: Function, Regulation and Gateways for Drug Delivery. 2017 , 54, 1046-1077	154
452	Impact of particle elasticity on particle-based drug delivery systems. 2017 , 108, 51-67	234
451	Nanoagonist-mediated endothelial tight junction opening: A strategy for safely increasing brain drug delivery in mice. 2017 , 37, 1410-1424	14
450	Convection-enhanced delivery in glioblastoma: a review of preclinical and clinical studies. 2017 , 126, 191-200	102
449	Non-invasive approaches for drug delivery to the brain based on the receptor mediated transport. 2017 , 76, 1316-1327	32
448	On glioblastoma and the search for a cure: where do we stand?. 2017 , 74, 2451-2466	37
447	Dual Modulation of Human P-Glycoprotein and ABCG2 with Prodrug Dimers of the Atypical Antipsychotic Agent Paliperidone in a Model of the Blood-Brain Barrier. 2017 , 14, 1107-1119	9
446	Emerging role of dopamine in neovascularization of pheochromocytoma and paraganglioma. 2017 , 31, 2226-2240	7
445	Recent progress in drug delivery of pluronic P123: pharmaceutical perspectives. 2017 , 25, 471-484	27
444	Novel Peptides Derived from Dengue Virus Capsid Protein Translocate Reversibly the Blood-Brain Barrier through a Receptor-Free Mechanism. 2017 , 12, 1257-1268	19
443	Thalamic mast cell activity is associated with sign-tracking behavior in rats. 2017 , 65, 222-229	5
442	Calixarene-mediated liquid membrane transport of choline conjugates 3: The effect of handle variation on neurotransmitter transport. 2017 , 27, 2953-2956	0
441	Lysosomal enzyme replacement therapies: Historical development, clinical outcomes, and future perspectives. 2017 , 118, 109-134	68
440	Selective small-molecule inhibitors as chemical tools to define the roles of matrix metalloproteinases in disease. 2017 , 1864, 2001-2014	16
439	CNS angiogenesis and barrierogenesis occur simultaneously. 2017 , 425, 101-108	50

438	Novel Focused Ultrasound Gene Therapy Approach Noninvasively Restores Dopaminergic Neuron Function in a Rat Parkinson's Disease Model. 2017 , 17, 3533-3542	87
437	Surface chemistry governs cellular tropism of nanoparticles in the brain. 2017 , 8, 15322	50
436	Intranasal drug delivery of small interfering RNA targeting Beclin1 encapsulated with polyethylenimine (PEI) in mouse brain to achieve HIV attenuation. 2017 , 7, 1862	58
435	Local DNA Repair Inhibition for Sustained Radiosensitization of High-Grade Gliomas. 2017 , 16, 1456-1469	22
434	In silico modeling on ADME properties of natural products: Classification models for blood-brain barrier permeability, its application to traditional Chinese medicine and in vitro experimental validation. 2017 , 75, 347-354	14
433	Dual-functional selenium nanoparticles bind to and inhibit amyloid β fiber formation in Alzheimer's disease. 2017 , 5, 5954-5967	35
432	Drug and Gene Delivery Materials and Devices. 2017 , 375-392	
431	Guiding Brain-Tumor Surgery via Blood-Brain-Barrier-Permeable Gold Nanoprobes with Acid-Triggered MRI/SERES Signals. 2017 , 29, 1603917	116
430	Bike peptides: a ride through the membrane. 2017 , 23, 294-302	8
429	Non-invasive aerosol delivery and transport of gold nanoparticles to the brain. 2017 , 7, 44718	35
428	Pericytes, an overlooked player in vascular pathobiology. 2017 , 171, 30-42	105
427	Medicinal Chemistry and Brain Drug Penetrance. 2017 , 831-845	
426	Novel Delivery Strategies. 2017 , 193-216	
425	Protein engineering approaches for regulating blood-brain barrier transcytosis. 2017 , 45, 109-115	35
424	Exogenous iron redistribution between brain and spleen after the administration of the $^{57}\text{Fe}3\text{O}_4$ ferrofluid into the ventricle of the brain. 2017 , 427, 41-47	9
423	Quantification of Transporter and Receptor Proteins in Dog Brain Capillaries and Choroid Plexus: Relevance for the Distribution in Brain and CSF of Selected BCRP and P-gp Substrates. 2017 , 14, 3436-3447	31
422	Zebrafish: A promising in vivo model for assessing the delivery of natural products, fluorescence dyes and drugs across the blood-brain barrier. 2017 , 125, 246-257	39
421	Neuroprotective action of undecylenic acid (UDA) encapsulated into PCL nanocarriers. 2017 , 532, 41-47	4

420	Traditional neurotherapeutics approach intended for direct nose to brain delivery. 2017 , 209, 116-123	12
419	Getting Drugs Across Biological Barriers. 2017 , 29, 1606596	97
418	Receptor Targeted Polymeric Nanostructures Capable of Navigating across the Blood-Brain Barrier for Effective Delivery of Neural Therapeutics. 2017 , 8, 2105-2117	10
417	Exogenous iron redistribution between brain and liver after administering 57Fe3O4 ferrofluid to a rat brain ventricle. 2017 , 81, 788-792	1
416	Blood-Brain barrier and laser technology for drug brain delivery. 2017 , 10, 1730011	2
415	IMM-H004, A New Coumarin Derivative, Improved Focal Cerebral Ischemia via Blood-Brain Barrier Protection in Rats. 2017 , 26, 2065-2073	14
414	Tumor-targeted nanotherapeutics: overcoming treatment barriers for glioblastoma. 2017 , 9, e1439	41
413	Primary Porcine Brain Endothelial Cells as In Vitro Model to Study Effects of Ultrasound and Microbubbles on Blood-Brain Barrier Function. 2017 , 64, 281-290	16
412	Phage display as a tool to discover blood-brain barrier (BBB)-shuttle peptides: panning against a human BBB cellular model. 2017 , 108, e22928	17
411	Pathways of protein and lipid receptor-mediated transcytosis in drug delivery. 2017 , 14, 341-351	25
410	Emerging therapies for neuropathic lysosomal storage disorders. 2017 , 152, 166-180	15
409	Delivery of Small Interfering RNA to Inhibit Vascular Endothelial Growth Factor in Zebrafish Using Natural Brain Endothelia Cell-Secreted Exosome Nanovesicles for the Treatment of Brain Cancer. 2017 , 19, 475-486	108
408	Blood-Brain Barrier and Cognitive Function. 2017 , 713-740	
407	The Physics of the Mind and Brain Disorders. 2017 ,	8
406	Improving Brain Delivery of Biomolecules via BBB Modulation in Mouse and Rat: Detection using MRI, NIRF, and Mass Spectrometry. 2017 , 1, 217-231	21
405	Photodynamic opening of blood-brain barrier. 2017 , 8, 5040-5048	32
404	Penetration of blood-brain barrier and antitumor activity and nerve repair in glioma by doxorubicin-loaded monosialoganglioside micelles system. 2017 , 12, 4879-4889	23
403	Nanotechnologies for brain tumor therapy. 2017 , 171-190	1

402	Angiopep-2-conjugated poly(ethylene glycol)-- poly(E-caprolactone) polymersomes for dual-targeting drug delivery to glioma in rats. 2017 , 12, 2117-2127	51
401	BloodBrain Barrier: Genomics, Proteomics, Disease Targets, and Drug Delivery. 2017 , 15-34	
400	Drug Delivery to the Brain: Pharmacokinetic Concepts. 2017 , 69-89	1
399	Increasing of Blood-Brain Tumor Barrier Permeability through Transcellular and Paracellular Pathways by Microbubble-Enhanced Diagnostic Ultrasound in a C6 Glioma Model. 2017 , 11, 86	17
398	Mapping Extracellular pH of Gliomas in Presence of Superparamagnetic Nanoparticles: Towards Imaging the Distribution of Drug-Containing Nanoparticles and Their Curative Effect on the Tumor Microenvironment. 2017 , 2017, 3849373	14
397	Brain Tumor Diagnostics and Therapeutics with Superparamagnetic Ferrite Nanoparticles. 2017 , 2017, 6387217	14
396	Nanosized Minicells Generated by Lactic Acid Bacteria for Drug Delivery. 2017 , 2017, 1-10	8
395	4.30 Nanomaterials for Drug Delivery to the Brain. 2017 , 549-570	
394	The Route of Nanomaterials Entering Brain. 2017 , 33-57	5
393	The Potential of Stimuli-Responsive Nanogels in Drug and Active Molecule Delivery for Targeted Therapy. 2017 , 3,	36
392	Effects on P-Glycoprotein Expression after Blood-Brain Barrier Disruption Using Focused Ultrasound and Microbubbles. 2017 , 12, e0166061	67
391	Identification of Novel Agents for the Treatment of Brain Metastases of Breast Cancer. 2017 , 17, 479-485	1
390	Development and Characterization of Methylene Blue Oleate Salt-Loaded Polymeric Nanoparticles and their Potential Application as a Treatment for Glioblastoma. 2017 , 8,	7
389	Brain Delivery of Multifunctional Dendrimer Protein Bioconjugates. 2018 , 5, 1700897	29
388	Matrix-assisted laser desorption/ionization imaging mass spectrometry of intraperitoneally injected danegaptide (ZP1609) for treatment of stroke-reperfusion injury in mice. 2018 , 32, 951-958	8
387	Evaluation of toxicity of glycerol monooleate nanoparticles on PC12 cell line. 2018 , 539, 23-30	6
386	Photodynamic opening of the blood-brain barrier and pathways of brain clearing. 2018 , 11, e201700287	29
385	Effect of Retro-Inverso Isomer of Bradykinin on Size-Dependent Penetration of Blood-Brain Tumor Barrier. 2018 , 14, 1702331	16

384	Crossing the blood-brain barrier with nanoparticles. 2018 , 270, 290-303	324
383	Formulation and In-vivo Pharmacokinetic Consideration of Intranasal Microemulsion and Mucoadhesive Microemulsion of Rivastigmine for Brain Targeting. 2018 , 35, 8	26
382	Visualizing glioma margins by real-time tracking of Glutamylnsptidase activity. 2018 , 173, 1-10	32
381	Liposomes and lipid disks traverse the BBB and BBTB as intact forms as revealed by two-step Förster resonance energy transfer imaging. 2018 , 8, 261-271	24
380	3D tissue engineering, an emerging technique for pharmaceutical research. 2018 , 8, 756-766	27
379	Plant protein-based hydrophobic fine and ultrafine carrier particles in drug delivery systems. 2018 , 38, 47-67	57
378	Nanotherapeutic systems for local treatment of brain tumors. 2018 , 10, e1479	39
377	RAGE-NF- κ B-PPAR γ Signaling is Involved in AGEs-Induced Upregulation of Amyloid- β Influx Transport in an In Vitro BBB Model. 2018 , 33, 284-299	13
376	Enhanced glioma therapy by synergistic inhibition of autophagy and tyrosine kinase activity. 2018 , 536, 1-10	20
375	Recent advances in nanomedicine and survivin targeting in brain cancers. 2018 , 13, 105-137	28
374	Abuse liability assessment for biologic drugs - All molecules are not created equal. 2018 , 92, 165-172	2
373	Overcoming the Blood-Brain Barrier: The Role of Nanomaterials in Treating Neurological Diseases. 2018 , 30, e1801362	226
372	From venoms to BBB-shuttles. MiniCTX3: a molecular vector derived from scorpion venom. 2018 , 54, 12738-12741	11
371	Polymer-Based Drug Delivery Systems for Cancer. 2018 , 35, 521-553	12
370	Simulations of blood as a suspension predicts a depth dependent hematocrit in the circulation throughout the cerebral cortex. 2018 , 14, e1006549	18
369	HAI Peptide and Backbone Analogs-Validation and Enhancement of Biostability and Bioactivity of BBB Shuttles. 2018 , 8, 17932	4
368	Analysis of Multifrequency and Phase Keying Strategies for Focusing Ultrasound to the Human Vertebral Canal. 2018 , 65, 2322-2331	13
367	Glioblastoma Chemoresistance: The Double Play by Microenvironment and Blood-Brain Barrier. 2018 , 19,	73

366	Toward Higher Sensitivity in Quantitative MALDI Imaging Mass Spectrometry of CNS Drugs Using a Nonpolar Matrix. 2018 , 90, 12592-12600	12
365	Blood-brain barrier disruption induced by diagnostic ultrasound combined with microbubbles in mice. 2018 , 9, 4897-4914	30
364	Whole Body Vibration Therapy after Ischemia Reduces Brain Damage in Reproductively Senescent Female Rats. 2018 , 19,	15
363	Multifunctional Nanoparticles for Successful Targeted Drug Delivery across the Blood-Brain Barrier. 2018 ,	6
362	Branched BBB-shuttle peptides: chemoselective modification of proteins to enhance blood-brain barrier transport. 2018 , 9, 8409-8415	24
361	Alterations in Cellular Processes Involving Vesicular Trafficking and Implications in Drug Delivery. 2018 , 3,	14
360	Liposomes and polymersomes: a comparative review towards cell mimicking. 2018 , 47, 8572-8610	458
359	models of molecular and nano-particle transport across the blood-brain barrier. 2018 , 12, 042213	45
358	Antisense oligonucleotides in neurological disorders. 2018 , 11, 1756286418776932	67
357	Trans-crocin 4 is not hydrolyzed to crocetin following i.p. administration in mice, while it shows penetration through the blood brain barrier. 2018 , 129, 62-72	12
356	Micelle-Based Drug Delivery for Brain Tumors. 2018 , 307-326	4
355	Advances in Patient-Specific Induced Pluripotent Stem Cells Shed Light on Drug Discovery for Amyotrophic Lateral Sclerosis. 2018 , 27, 1301-1312	9
354	Cell Specific Changes of Autophagy in a Mouse Model of Contusive Spinal Cord Injury. 2018 , 12, 164	15
353	Nose-to-Brain Delivery of Antiviral Drugs: A Way to Overcome Their Active Efflux?. 2018 , 10,	20
352	Localized delivery of curcumin into brain with polysorbate 80-modified cerasomes by ultrasound-targeted microbubble destruction for improved Parkinson's disease therapy. 2018 , 8, 2264-2277	94
351	Nanoparticle formulations that allow for sustained delivery and brain targeting of the neuropeptide oxytocin. 2018 , 548, 698-706	19
350	Nanoparticle Formulation Derived from Carboxymethyl Cellulose, Polyethylene Glycol, and Cabazitaxel for Chemotherapy Delivery to the Brain. 2018 , 29, 2009-2020	11
349	Systems engineers' role in biomedical research. Convection-enhanced drug delivery. 2018 , 271-302	5

348	DPCPX, a selective adenosine A1 receptor antagonist, enhances the antidepressant-like effects of imipramine, escitalopram, and reboxetine in mice behavioral tests. 2018 , 391, 1361-1371	10
347	Advances in Nanomaterials for Brain Microscopy. 2018 , 11, 5144-5172	10
346	Investigation on the effect of nanoparticle size on the blood-brain tumour barrier permeability by in situ perfusion via internal carotid artery in mice. 2019 , 27, 103-110	27
345	Local strategies and delivery systems for the treatment of malignant gliomas. 2019 , 27, 367-378	9
344	A new descriptor via bio-mimetic chromatography and modeling for the blood brain barrier (Part II). 2019 , 164, 808-817	3
343	Development and screening of brain-targeted lipid-based nanoparticles with enhanced cell penetration and gene delivery properties. 2019 , 14, 6497-6517	26
342	Altered Biodistribution and Tissue Retention of Nanoparticles Targeted with P-Glycoprotein Substrates. 2019 , 5, 308-318	0
341	Cell and Gene Therapies for Mucopolysaccharidoses: Base Editing and Therapeutic Delivery to the CNS. 2019 , 7,	5
340	SIRT1 activation alleviates brain microvascular endothelial dysfunction in peroxisomal disorders. 2019 , 44, 995-1005	9
339	gH625-liposomes as tool for pituitary adenylate cyclase-activating polypeptide brain delivery. 2019 , 9, 9183	10
338	Translational prospects of untethered medical microrobots. 2019 , 1, 012002	70
337	Liposomal Formulations for Nose-to-Brain Delivery: Recent Advances and Future Perspectives. 2019 , 11,	51
336	Computational Nanoscopy of Tight Junctions at the Blood-Brain Barrier Interface. 2019 , 20,	11
335	Comparison of intranasal versus intravenous midazolam for management of status epilepticus in dogs: A multi-center randomized parallel group clinical study. 2019 , 33, 2709-2717	10
334	Study on the Material Basis of Neuroprotection of Bark. 2019 , 24,	3
333	Magnetic Functionalized Nanoparticles for Biomedical, Drug Delivery and Imaging Applications. 2019 , 14, 188	102
332	A Human Immortalized Cell-Based Blood-Brain Barrier Triculture Model: Development and Characterization as a Promising Tool for Drug-Brain Permeability Studies. 2019 , 16, 4461-4471	15
331	The cerebral angiome: High resolution MicroCT imaging of the whole brain cerebrovasculature in female and male mice. 2019 , 202, 116109	14

330	Targeting strategies for improving the efficacy of nanomedicine in oncology. 2019 , 10, 168-181	36
329	Inhibition of metal-induced amyloid peptide aggregation by a blood-brain barrier permeable silica-cyclen nanochelator.. 2019 , 9, 14126-14131	6
328	The impact of lactic acid and medium chain triglyceride on blood glucose, lactate and diurnal motor activity: A re-examination of a treatment of major depression using lactic acid. 2019 , 208, 112569	3
327	Advancements in Canadian Biomaterials Research in Neurotraumatic Diagnosis and Therapies. 2019 , 7, 336	1
326	Neuroprotective Potential of Curcumin-Loaded Nanostructured Lipid Carrier in an Animal Model of Alzheimer's Disease: Behavioral and Biochemical Evidence. 2019 , 69, 671-686	41
325	Drug Delivery Technology to the CNS in the Treatment of Brain Tumors: The Sherbrooke Experience. 2019 , 11,	5
324	Targeting Strategies. 2019 , 195-263	
323	T cell immunotherapy enhanced by designer biomaterials. 2019 , 217, 119265	24
322	Can we overcome the most significant barrier to treatment of neurodegenerative disorders?. 2019 , 303, 319-320	
321	Suppressing nNOS Enzyme by Small-Interfering RNAs Protects SH-SY5Y Cells and Nigral Dopaminergic Neurons from 6-OHDA Injury. 2019 , 36, 117-131	5
320	A Novel Contrast Agent Based on Magnetic Nanoparticles for Cholesterol Detection as Alzheimer's Disease Biomarker. 2019 , 14, 36	9
319	Targeting of Thymoquinone-loaded mesoporous silica nanoparticles to different brain areas: In vivo study. 2019 , 222, 94-102	22
318	Magnetically guided non-invasive CRISPR-Cas9/gRNA delivery across blood-brain barrier to eradicate latent HIV-1 infection. 2019 , 9, 3928	53
317	Progress in neuromodulation of the brain: A role for magnetic nanoparticles?. 2019 , 177, 1-14	35
316	Nanotechnology approaches for enhanced CNS delivery in treating Alzheimer's disease. 2019 , 51, 297-309	11
315	Exosomes as Drug Carriers for Cancer Therapy. 2019 , 16, 1789-1798	83
314	Multifunctionalized Ferri-liposomes for Hyperthermia Induced Glioma Targeting and Brain Drug Delivery. 2019 , 1-16	
313	Entry of therapeutics into the brain: Influence of exposed polarity calculated in silico and measured in vitro by supercritical fluid chromatography. 2019 , 560, 294-305	7

312	Blood-Brain Barrier-Targeted Nanotechnological Advances. 2019 , 25-31	
311	Biomaterials for local drug delivery in central nervous system. 2019 , 560, 92-100	10
310	Linking the low-density lipoprotein receptor-binding segment enables the therapeutic 5-YHEDA peptide to cross the blood-brain barrier and scavenge excess iron and radicals in the brain of senescent mice. 2019 , 5, 717-731	3
309	IVIVC Assessment of Two Mouse Brain Endothelial Cell Models for Drug Screening. 2019 , 11,	9
308	Transcytosis - An effective targeting strategy that is complementary to "EPR effect" for pancreatic cancer nano drug delivery. 2019 , 9, 8018-8025	54
307	Engineered nanoparticles for systemic siRNA delivery to malignant brain tumours. 2019 , 11, 20045-20057	26
306	I6P7 peptide modified superparamagnetic iron oxide nanoparticles for magnetic resonance imaging detection of low-grade brain gliomas. 2019 , 7, 6139-6147	5
305	Dendrimer-Based Drug Delivery Systems for Brain Targeting. 2019 , 9,	58
304	Identification of Blood-Brain Barrier-Permeable Proteins Derived from a Peripheral Organ: In Vivo and in Vitro Evidence of Blood-to-Brain Transport of Creatine Kinase. 2019 , 16, 247-257	3
303	Zebrafish (<i>Danio rerio</i>) as a Viable Model to Study the Blood-Brain Barrier. 2019 , 187-196	1
302	Chemoresistance caused by the microenvironment of glioblastoma and the corresponding solutions. 2019 , 109, 39-46	25
301	Perspective on brain targeting drug delivery systems. 2019 , 455-467	4
300	Using the synthesized peptide HAYED (5) to protect the brain against iron catalyzed radical attack in a naturally senescence Kunming mouse model. 2019 , 130, 458-470	6
299	Carrier-mediated transportation through BBB. 2019 , 129-158	6
298	Recent progress in blood-brain barrier transportation research. 2019 , 33-51	8
297	Nano-Based Carriers for Brain Drug Delivery. 2019 , 563-586	
296	In vitro and in vivo models of BBB to evaluate brain targeting drug delivery. 2019 , 53-101	7
295	Trends in Nanotechnology for Practical Applications. 2019 , 297-325	5

294	Photosensitizing materials and platforms for light-triggered modulation of Alzheimer's Amyloid self-assembly. 2019 , 190-191, 121-132	36
293	Brain-derived neurotrophic factor alleviates the oxidative stress induced by oxygen and glucose deprivation in an ex vivo brain slice model. 2019 , 234, 9592-9604	5
292	Brain Delivery of Curcumin Using Solid Lipid Nanoparticles and Nanostructured Lipid Carriers: Preparation, Optimization, and Pharmacokinetic Evaluation. 2019 , 10, 728-739	82
291	Penetration of the blood-brain barrier by peripheral neuropeptides: new approaches to enhancing transport and endogenous expression. 2019 , 375, 287-293	18
290	Blood-Brain Barrier. 2019 ,	3
289	Synergistic anticancer activity by co-delivered nanosized dual therapeutic agents and siRNA in colon cancer. 2020 , 55, 101351	3
288	Microengineered human blood-brain barrier platform for understanding nanoparticle transport mechanisms. 2020 , 11, 175	120
287	Biomimetic drug-delivery systems for the management of brain diseases. 2020 , 8, 1073-1088	17
286	Nucleic Acid Aptamers for Molecular Therapy of Epilepsy and Blood-Brain Barrier Damages. 2020 , 19, 157-167	13
285	mGluR5 Allosteric Modulation Promotes Neurorecovery in a 6-OHDA-Toxicant Model of Parkinson's Disease. 2020 , 57, 1418-1431	11
284	Gamma radiation preparation of chitosan nanoparticles for controlled delivery of memantine. 2020 , 34, 1150-1162	11
283	Sphenopalatine Ganglion Stimulation Upregulates Transport of Temozolomide across the Blood-Brain Barrier. 2020 , 88, 40	
282	Intranasal administration of gold nanoparticles designed to target the central nervous system: Fabrication and comparison between nanospheres and nanoprisms. 2020 , 590, 119957	7
281	Development and Clinical Application of Phosphorus-Containing Drugs. 2020 , 8, 100063	26
280	Acetylcholinesterase inhibitory activity, anti-inflammatory, and neuroprotective potential of Hipppeastrum psittacinum (Ker Gawl.) herb (Amaryllidaceae). 2020 , 145, 111703	7
279	Neuronal Activity Regulates Blood-Brain Barrier Efflux Transport through Endothelial Circadian Genes. 2020 , 108, 937-952.e7	27
278	A Porcine Model of Transvertebral Ultrasound and Microbubble-Mediated Blood-Spinal Cord Barrier Opening. 2020 , 10, 7758-7774	6
277	Development of an LDL Receptor-Targeted Peptide Susceptible to Facilitate the Brain Access of Diagnostic or Therapeutic Agents. 2020 , 9,	5

276	Biomedical engineering approaches to enhance therapeutic delivery for malignant glioma. 2020 , 328, 917-931	10
275	A blood-brain barrier overview on structure, function, impairment, and biomarkers of integrity. 2020 , 17, 69	123
274	Coculture model of blood-brain barrier on electrospun nanofibers. 2020 , 44, 121-132	1
273	CNS-Targeting Therapies for Lysosomal Storage Diseases: Current Advances and Challenges. 2020 , 7, 559804	14
272	Neurotransmitter-derived lipidoids (NT-lipidoids) for enhanced brain delivery through intravenous injection. 2020 , 6, eabb4429	24
271	Estimating Brain Permeability Using In Vitro Blood-Brain Barrier Models. 2021 , 2367, 47-72	8
270	Epilepsy and Alterations of the Blood-Brain Barrier: Cause or Consequence of Epileptic Seizures or Both?. 2020 , 1	6
269	Nose-to-Brain Translocation and Cerebral Biodegradation of Thin Graphene Oxide Nanosheets. 2020 , 1, 100176	8
268	Strategies and materials of "SMART" non-viral vectors: Overcoming the barriers for brain gene therapy. 2020 , 35, 101006	7
267	Overview of Current Drug Delivery Methods Across the Blood-Brain Barrier for the Treatment of Primary Brain Tumors. 2020 , 34, 1121-1131	35
266	Advanced polymeric nanotechnology to augment therapeutic delivery and disease diagnosis. 2020 , 15, 2287-2309	2
265	Effect of Nanoparticle Composition, Size, Shape, and Stiffness on Penetration Across the Blood-Brain Barrier. 2020 , 6, 4916-4928	35
264	Immunotherapy for Glioblastoma: Current State, Challenges, and Future Perspectives. 2020 , 12,	4
263	Advancements in the Blood-Brain Barrier Penetrating Nanoplatforms for Brain Related Disease Diagnostics and Therapeutic Applications. 2020 , 12,	17
262	Overcoming the Blood-Brain Barrier: Functionalised Chitosan Nanocarriers. 2020 , 12,	11
261	Evaluation of the Influence of Astrocytes on Blood-Brain Barrier Models. 2020 , 48, 184-200	3
260	Fast Estimation of the Blood-Brain Barrier Permeability by Pulling a Ligand through a Lipid Membrane. 2020 , 60, 3057-3067	10
259	Actively targeted gold nanoparticle composites improve behavior and cognitive impairment in Parkinson's disease mice. 2020 , 114, 111028	10

258	The Isolated Brain Microvessel: A Versatile Experimental Model of the Blood-Brain Barrier. 2020 , 11, 398	20
257	In Vitro Models of the Blood-Brain Barrier. 2021 , 265, 75-110	7
256	Baseline requirements for novel agents being considered for phase II/III brain cancer efficacy trials: conclusions from the Adult Brain Tumor Consortium's first workshop on CNS drug delivery. 2020 , 22, 1422-1424	9
255	Protein corona formation moderates the release kinetics of ion channel antagonists from transferrin-functionalized polymeric nanoparticles.. 2020 , 10, 2856-2869	5
254	Building and Testing PPAR γ Therapeutic ELB00824 with an Improved Therapeutic Window for Neuropathic Pain. 2020 , 25,	1
253	Tumor Necrosis Factor (TNF) blocking agents are associated with lower risk for Alzheimer's disease in patients with rheumatoid arthritis and psoriasis. 2020 , 15, e0229819	36
252	Microtube-Embedded Microfluidic Devices for Potential Applications in Blood Brain Barrier Research. 2020 , 48, 294-301	4
251	Expression and Cellular Distribution of P-Glycoprotein and Breast Cancer Resistance Protein in Amyotrophic Lateral Sclerosis Patients. 2020 , 79, 266-276	8
250	Ultrasound-induced blood-brain barrier disruption for the treatment of gliomas and other primary CNS tumors. 2020 , 479, 13-22	16
249	Drug delivery across the blood-brain barrier: recent advances in the use of nanocarriers. 2020 , 15, 205-214	52
248	Structural, Molecular, and Functional Alterations of the Blood-Brain Barrier during Epileptogenesis and Epilepsy: A Cause, Consequence, or Both?. 2020 , 21,	61
247	Persistent prolate polymersomes for enhanced co-delivery of hydrophilic and hydrophobic drugs. 2020 , 31, 175103	4
246	Multimodal and multiscale optical imaging of nanomedicine delivery across the blood-brain barrier upon sonopermeation. 2020 , 10, 1948-1959	14
245	Dense hydroxyl polyethylene glycol dendrimer targets activated glia in multiple CNS disorders. 2020 , 6, eaay8514	29
244	Collagen-curcumin nanocomposites showing an enhanced neuroprotective effect against short term focal cerebral ischemia.. 2020 , 10, 2241-2253	2
243	Antibodies for the Treatment of Brain Metastases, a Dream or a Reality?. 2020 , 12,	17
242	Steroid Hormone Entry into the Brain Requires a Membrane Transporter in Drosophila. 2020 , 30, 359-366.e3	14
241	Molecular Probe Crossing BloodBrain Barrier for Bimodal Imaging-Guided Photothermal/Photodynamic Therapies of Intracranial Glioblastoma. 2020 , 30, 1909117	18

240	Influence of the endocannabinoid system on the antidepressant activity of bupropion and moclobemide in the behavioural tests in mice. 2020 , 72, 1562-1572	5
239	Periphery-confined particulate systems for the management of neurodegenerative diseases and toxicity: Avoiding the blood-brain-barrier challenge. 2020 , 322, 286-299	6
238	A comprehensive review of nano drug delivery system in the treatment of CNS disorders. 2020 , 57, 101628	10
237	Amphetamine decorated cationic lipid nanoparticles cross the blood-brain barrier: therapeutic promise for combating glioblastoma. 2020 , 8, 4318-4330	17
236	Water-soluble variant of human Lynx1 positively modulates synaptic plasticity and ameliorates cognitive impairment associated with α -nAChR dysfunction. 2020 , 155, 45-61	11
235	The Promise and Challenges of Developing miRNA-Based Therapeutics for Parkinson's Disease. 2020 , 9,	23
234	Biomedical Micro-/Nanomotors: From Overcoming Biological Barriers to In Vivo Imaging. 2021 , 33, e2000512	80
233	Treating brain diseases using systemic parenterally-administered protein therapeutics: Dysfunction of the brain barriers and potential strategies. 2021 , 269, 120461	2
232	self-organized three-dimensional model of the blood-brain barrier microvasculature. 2020 ,	6
231	Injectable thermoresponsive hydrogels as drug delivery system for the treatment of central nervous system disorders: A review. 2021 , 329, 16-35	25
230	Basic physiology of the blood-brain barrier in health and disease: a brief overview. 2021 , 9, 1840913	5
229	Neurodegenerative diseases and effective drug delivery: A review of challenges and novel therapeutics. 2021 , 330, 1152-1167	26
228	Dopamine-conjugated CuS/chitosan nanocomposite for targeted photothermal drug delivery: In vitro cytotoxicity study to establish bio-compatibility. 2021 , 61, 102193	8
227	Emerging Role of Nanomedicine for Targeted Drug Delivery in Brain Tumor. 2021 , 123-139	0
226	Brain-Derived Neurotrophic Factor and Stem Cell-Based Technologies in Huntington's Disease Therapy.	0
225	Functional nanoassemblies for the diagnosis and therapy of Alzheimer's diseases. 2021 , 13, e1696	1
224	A Destruction Model of the Vascular and Lymphatic Systems in the Emergence of Psychiatric Symptoms. 2021 , 10,	2
223	Parkinson's disease. 2021 , 491-513	

222	Curcumin loaded drug delivery systems in Parkinson's disease. 2021 , 105-119	
221	Pro- and Anti-inflammatory Neurovascular Processes in Epilepsy: A Fragile and Dynamic Equilibrium. 2021 , 1-20	
220	Brain penetrating peptides and peptide-drug conjugates to overcome the blood-brain barrier and target CNS diseases. 2021 , 13, e1695	18
219	Development of L-carnosine functionalized iron oxide nanoparticles loaded with dexamethasone for simultaneous therapeutic potential of blood brain barrier crossing and ischemic stroke treatment. 2021 , 28, 380-389	14
218	Modified biopolymer-based systems for drug delivery to the brain. 2021 , 571-611	2
217	Blood-Brain Barrier Disruption: A Common Driver of Central Nervous System Diseases. 2021 , 1073858420985838	
216	Development, Characterization and Potential Applications of a Multicellular Spheroidal Human Blood-Brain Barrier Model Integrating Three Conditionally Immortalized Cell Lines. 2021 , 44, 984-991	0
215	Microemulsion-Based Media in Nose-to-Brain Drug Delivery. 2021 , 13,	14
214	An Improved Method for Physical Separation of Cerebral Vasculature and Parenchyma Enables Detection of Blood-Brain-Barrier Dysfunction. 2021 , 2, 59-74	1
213	Efficient LRP1-Mediated Uptake and Low Cytotoxicity of Peptide L57 In Vitro Shows Its Promise as CNS Drug Delivery Vector. 2021 , 110, 824-832	2
212	The Neurovascular Unit Dysfunction in Alzheimer's Disease. 2021 , 22,	25
211	The Role of Nanomaterials in Stroke Treatment: Targeting Oxidative Stress. 2021 , 2021, 8857486	7
210	Curcumin Loaded and Co-loaded Nanosystems: A Review from a Biological Activity Enhancement Perspective. 2021 , 9, 85-100	1
209	Synthesis and biological evaluation of a ring analogs of the selective CB2 inverse agonist SMM-189. 2021 , 33, 116035	2
208	Artificial neural network approach for predicting blood brain barrier permeability based on a group contribution method. 2021 , 200, 105943	1
207	Ultrasound Combined With Microbubbles Loading BDNF Retrovirus to Open BloodBrain Barrier for Treatment of Alzheimer's Disease. 2021 , 12, 615104	6
206	Microemulsion as a promising carrier for nose to brain delivery: journey since last decade. 2021 , 51, 611	3
205	Assessment of brain-to-blood drug distribution using liquid chromatography. 2021 , 35, e5123	1

204	The Role of Permeability in Drug ADME/PK, Interactions and Toxicity, and the Permeability-Based Classification System (PCS). 1-14	
203	Targeting the blood-brain barrier for the delivery of stroke therapies. 2021 , 171, 332-351	19
202	Delivery of oligonucleotide-based therapeutics: challenges and opportunities. 2021 , 13, e13243	54
201	Transferrin-functionalized lipid nanoparticles for curcumin brain delivery. 2021 , 331, 108-117	10
200	Causes of drug resistance and glioblastoma relapses. 2021 , 11, 101-108	
199	Delivery of Therapeutic Agents to the Central Nervous System and the Promise of Extracellular Vesicles. 2021 , 13,	6
198	Development of immunotherapy and nanoparticles-based strategies for the treatment of Parkinson's disease. 2021 , 51, 465	5
197	Design and synthesis of N-hydroxyalkyl substituted deferiprone: a kind of iron chelating agents for Parkinson's disease chelation therapy strategy. 2021 , 26, 467-478	1
196	Three-Dimensional Models of Healthy and Tumor Brain Microvasculature for Drug and Toxicity Screening.. 2021 , 3, 656254	5
195	Kappa-opioid receptor-mediated thermal analgesia evoked by the intrathecal administration of the chemokine CCL1 in mice. 2021 , 35, 1109-1118	0
194	Nanomaterials to Fight Cancer: An Overview on Their Multifunctional Exploitability. 2021 , 21, 2760-2777	
193	Development of an a priori computational approach for brain uptake of compounds in an insect model system. 2021 , 40, 127930	1
192	Retinal Ganglion Cell Transplantation: Approaches for Overcoming Challenges to Functional Integration. 2021 , 10,	4
191	Emerging two-dimensional materials-enabled diagnosis and treatments of Alzheimer's disease: Status and future challenges. 2021 , 23, 101028	1
190	A Nanoantidote Alleviates Glioblastoma Chemotoxicity without Efficacy Compromise. 2021 , 21, 5158-5166	5
189	Artificial intelligence and guidance of medicine in the bubble. 2021 , 11, 108	4
188	Targeting receptor-ligand chemistry for drug delivery across blood-brain barrier in brain diseases. 2021 , 274, 119326	8
187	Potential Roles for Gamma-Aminobutyric Acid Signaling in Bacterial Communities. 2021 , 3, 120-125	0

186	Ultrasound-activated nano-TiO ₂ loaded with temozolomide paves the way for resection of chemoresistant glioblastoma multiforme. 2021 , 12,		3
185	Cryogel biomaterials for neuroscience applications. 2021 , 147, 105012		12
184	Brain safety concerns of nanomedicines: The need for a specific regulatory framework. <i>Drug Discovery Today</i> , 2021 , 26, 2502-2507	8.8	0
183	Targeting Systems to the Brain Obtained by Merging Prodrugs, Nanoparticles, and Nasal Administration. 2021 , 13,		1
182	Current status and future prospects of nanomedicine for arsenic trioxide delivery to solid tumors. 2022 , 42, 374-398		3
181	Therapeutic potential of nanoemulsions as feasible wagons for targeting Alzheimer's disease. <i>Drug Discovery Today</i> , 2021 , 26, 2881-2888	8.8	8
180	Usefulness of cell-penetrating peptides and penetration accelerating sequence for nose-to-brain delivery of glucagon-like peptide-2. 2021 , 335, 575-583		3
179	GSK-3 β /FYN, and DYRK1A: Master Regulators in Neurodegenerative Pathways. 2021 , 22,		16
178	Polymeric nanotherapeutics acting at special regions of body. 2021 , 64, 102597		7
177	Recent advances in nano delivery systems for blood-brain barrier (BBB) penetration and targeting of brain tumors. <i>Drug Discovery Today</i> , 2021 , 26, 1944-1952	8.8	23
176	B3Pred: A Random-Forest-Based Method for Predicting and Designing Blood-Brain Barrier Penetrating Peptides. 2021 , 13,		3
175	Dual Blood-Brain Barrier-Glioma Targeting Peptide-Poly(levodopamine) Hybrid Nanoplatforms as Potential Near Infrared Phototheranostic Agents in Glioblastoma. 2021 , 32, 2014-2031		0
174	Physical Exercise Modulates Brain Physiology Through a Network of Long- and Short-Range Cellular Interactions. 2021 , 14, 710303		1
173	Nanostructured lipid base carrier for specific delivery of garlic oil through blood brain barrier against aggressiveness of glioma. 2021 , 64, 102651		3
172	Dynamic nanoassemblies for imaging and therapy of neurological disorders. 2021 , 175, 113832		0
171	Electrokinetic-Noise-Assisted Barrier Crossing in a Nanofluidic Environment. 2021 , 16,		
170	Ultrasound-Mediated Blood-Brain Barrier Opening Improves Whole Brain Gene Delivery in Mice. 2021 , 13,		3
169	A Quasi-Physiological Microfluidic Blood-Brain Barrier Model for Brain Permeability Studies. 2021 , 13,		3

168	Recent Strategies to Develop Innovative Photosensitizers for Enhanced Photodynamic Therapy. 2021 , 121, 13454-13619	90
167	Design, Docking Simulations, Synthesis, and in vitro and in vivo Behavioral Assessment of π -Aminobenzoic Acid Analogues as GABA-AT Inhibitors. 2021 , 6, 8959-8970	
166	Xenobiotic transport and metabolism in the human brain. 2021 , 86, 125-138	2
165	The Transporter-Mediated Cellular Uptake and Efflux of Pharmaceutical Drugs and Biotechnology Products: How and Why Phospholipid Bilayer Transport Is Negligible in Real Biomembranes. 2021 , 26,	2
164	Lipid shell lipid nanocapsules as smart generation lipid nanocarriers. 2021 , 339, 117145	5
163	Targeting transthyretin in Alzheimer's disease: Drug discovery of small-molecule chaperones as disease-modifying drug candidates for Alzheimer's disease. 2021 , 226, 113847	2
162	In Vitro Human Blood-Brain Barrier Model for Drug Permeability Testing. 2021 , 2367, 73-85	2
161	On further development of barrier modulation as a technique for systemic ocular drug delivery. 2012 , 723, 155-9	5
160	MRI-Guided Focused Ultrasound. 2014 , 403-412	1
159	Nanoparticle Functionalization for Brain Targeting Drug Delivery and Diagnostic. 2016 , 941-959	2
158	BloodBrain barrier tissue engineering. 2020 , 425-439	2
157	Magnetic nanoemulsions as candidates for Alzheimer's disease dual imaging theranostics. 2020 , 31, 465702	3
156	Physical insights into the blood-brain barrier translocation mechanisms. 2017 , 14, 041001	22
155	Metal chelators coupled with nanoparticles as potential therapeutic agents for Alzheimer's disease. 2009 , 1, 42-55	26
154	Upregulation of BDNF and hippocampal functions by a hippocampal ligand of PPAR δ . 2020 , 5,	8
153	Systemic combinatorial peptide selection yields a non-canonical iron-mimicry mechanism for targeting tumors in a mouse model of human glioblastoma. 2011 , 121, 161-73	110
152	Charting the course across the blood-brain barrier. 2011 , 121, 31-3	27
151	Conjugation of a brain-penetrant peptide with neurotensin provides antinociceptive properties. 2014 , 124, 1199-213	69

150	Forensic Aspects of Intracranial Equilibria. 2014 , 363-416	2
149	A carrier for non-covalent delivery of functional beta-galactosidase and antibodies against amyloid plaques and IgM to the brain. 2011 , 6, e28881	41
148	The influence of spin-labeled fluorene compounds on the assembly and toxicity of the α peptide. 2012 , 7, e35443	13
147	Controlled ultrasound-induced blood-brain barrier disruption using passive acoustic emissions monitoring. 2012 , 7, e45783	120
146	Targeted delivery of GDNF through the blood-brain barrier by MRI-guided focused ultrasound. 2012 , 7, e52925	42
145	Selective inhibition of matrix metalloproteinase-9 attenuates secondary damage resulting from severe traumatic brain injury. 2013 , 8, e76904	82
144	P-glycoprotein mediated efflux limits the transport of the novel anti-Parkinson's disease candidate drug FLZ across the physiological and PD pathological in vitro BBB models. 2014 , 9, e102442	12
143	Chondroitinase ABC I-mediated enhancement of oncolytic virus spread and anti tumor efficacy: a mathematical model. 2014 , 9, e102499	23
142	A nanostructure of functional targeting epirubicin liposomes dually modified with aminophenyl glucose and cyclic pentapeptide used for brain glioblastoma treatment. 2015 , 6, 32681-700	29
141	Phytochemical-Mediated Glioma Targeted Treatment: Drug Resistance and Novel Delivery Systems. 2020 , 27, 599-629	4
140	Combinatorial approaches for the identification of brain drug delivery targets. 2014 , 20, 1564-76	15
139	PepH3, an Improved Peptide Shuttle for Receptor-independent Transport Across the Blood-Brain Barrier. 2020 , 26, 1495-1506	9
138	Drug Development for Central Nervous System Diseases Using In vitro Blood-brain Barrier Models and Drug Repositioning. 2020 , 26, 1466-1485	10
137	Brain Drug Delivery: Overcoming the Blood-brain Barrier to Treat Tauopathies. 2020 , 26, 1448-1465	0
136	Current Developments in Targeted Drug Delivery Systems for Glioma. 2020 , 26, 3973-3984	6
135	Blood-brain barrier P450 enzymes and multidrug transporters in drug resistance: a synergistic role in neurological diseases. 2011 , 12, 742-9	48
134	Alzheimer's Disease Targeted Nano-Based Drug Delivery Systems. 2020 , 21, 628-646	7
133	Blood-brain barrier disruption with low-intensity pulsed ultrasound for the treatment of pediatric brain tumors: a review and perspectives. 2020 , 48, E10	13

- 132 A Blood-brain Barrier Permeable Derivative of 5-Fluorouracil: Preparation, Intracellular Localization, and Mouse Tissue Distribution. **2011**, 32, 873-879 12
- 131 Central nervous system diseases and the role of the blood-brain barrier in their treatment. **2013**, 1, 3 17
- 130 Challenges and Prospects for Designer T and NK Cells in Glioblastoma Immunotherapy. **2021**, 13, 1
- 129 Therapeutic antibodies - natural and pathological barriers and strategies to overcome them. **2021**, 108022 1
- 128 Highly Specific Blood-Brain Barrier Transmigrating Single-Domain Antibodies Selected by an In Vivo Phage Display Screening. **2021**, 13, 1
- 127 Forensic Aspects of Intracranial Equilibria JAN E. LEESTMA, MD, MM. **2008**, 373-428
- 126 Brain Tumors: Convection-Enhanced Delivery of Drugs (Method). **2011**, 207-216
- 125 The Role of Drug Transporters on Psychotropic Penetration of the Blood–Brain Barrier. **2012**, 3, 8-14
- 124 Hematopoietic Growth Factor Family for Stroke Drug Development. **2012**, 251-276
- 123 Pharmacotherapy in the Neurosurgical Intensive Care Unit. **2013**, 941-963
- 122 Osmotic Opening of the BBB for Drug Treatment of Brain Tumors (Focus on Methodological Issues). **2014**, 519-543
- 121 Nanoparticles and CNS Delivery of Therapeutic Agents in the Treatment of Primary Brain Tumors. **2014**, 3, 105-112 1
- 120 Forensic Aspects of Intracranial Equilibria JAN E. LEESTMA. **2014**, 386-439
- 119 Nanoparticle Functionalization for Brain Targeting Drug Delivery and Diagnostic. **2015**, 1-16
- 118 BloodBrain barrier and drug delivery. **2015**, 6-21
- 117 Brain Effect Site Pharmacokinetics: Delivery of Biologics Across the BloodBrain Barrier. 1-16
- 116 8 Role of cell death pathways in response to photodynamic therapy in gliomas. **2017**, 131-148
- 115 Chemotherapeutic Strategies in Brain Tumors. **2018**, 89-104

114	Optimization of Photodynamic Effects on Permeability of Cerebral Vessels. 2018 , 18, 423-428	
113	Preclinical Non-invasive Imaging in Cancer Research and Drug Discovery: An Overview. 2019 , 419-469	
112	Tumor Necrosis Factor (TNF) Blocking Agents are Associated with Lower Risk for Alzheimer's Disease in Patients with Rheumatoid Arthritis and Psoriasis.	
111	Using RNA Interference for Purinoceptor Knockdown In Vivo. 2020 , 2041, 77-86	
110	A Review: Nose to Brain Drug Delivery for Various CNS Disorders. 2020 , 375-385	1
109	Genome Medicine for Brain Tumors: Current Status and Future Perspectives. 2020 , 60, 531-542	2
108	Nanoparticle designs for delivery of nucleic acid therapeutics as brain cancer therapies. 2021 , 179, 113999	6
107	A curated diverse molecular database of blood-brain barrier permeability with chemical descriptors. 2021 , 8, 289	5
106	Triolein emulsion enhances temozolomide brain delivery: an experimental study in rats. 2021 , 28, 2373-2382	0
105	Persistent Prolate Polymersomes for Enhanced Co-Delivery of Hydrophilic and Hydrophobic Drugs.	
104	Construction of Cationic Virosome Derived from Vesicular Stomatitis Virus as a Promising Candidate for Efficient Gene Delivery to the Central Nervous System. 2020 , 8, 72-81	
103	Wnt Signaling in Inner Blood-Retinal Barrier Maintenance. 2021 , 22,	1
102	Magnetic Nanoparticles as Delivery Systems to Penetrate the Blood-Brain Barrier. 2021 , 173-208	1
101	Evolving Drug Delivery Strategies to Overcome the Blood Brain Barrier. 2016 , 22, 1177-1193	74
100	Alcohol, inflammation, and blood-brain barrier function in health and disease across development. 2022 , 161, 209-249	3
99	Special delEVery: Extracellular Vesicles as Promising Delivery Platform to the Brain. 2021 , 9,	5
98	Dynamic 3D On-Chip BBB Model Design, Development, and Applications in Neurological Diseases. 2021 , 10,	5
97	PET Radiopharmaceutical Development. 2022 , 9-16	

96	Organelle-level precision with next-generation targeting technologies.	14
95	Studies on Antimicrobial, Antibiofilm, Efflux Pump Inhibiting, and ADMET Properties of Newly Synthesized 1,3,4-Thiadiazole Derivatives**. 2021 , 6, 12571-12581	1
94	Studies on some neuropharmacological properties of Nevirapine in mice.. 2022 , 12, 12-19	1
93	Exploring lipophilic compounds that induce BDNF secretion in astrocytes beyond the BBB using a new multi-cultured human in vitro BBB model.. 2022 , 362, 577783	
92	A Multiplexed Microfluidic Device to Measure Blood-Brain Barrier Disruption by Pulsed Electric Fields. 2021 , 2021, 1222-1225	1
91	Large-Scale Evaluation of Collision Cross Sections to Investigate Blood-Brain Barrier Permeation of Drugs.. 2021 , 13,	0
90	Efficiency of lipid-based nano drug delivery systems in crossing the bloodBrain barrier: A review. 2022 , 346, 118278	2
89	Opioid Use, Gut Dysbiosis, Inflammation, and the Nervous System.. 2022 , 1	0
88	Do Periodontal Pathogens or Associated Virulence Factors Have a Deleterious Effect on the Blood-Brain Barrier, Contributing to Alzheimer's Disease?. 2021 ,	0
87	Identification of novel bioactive compounds from Olea europaea by evaluation of chemical compounds in the OliveNetLibrary: in silico bioactivity and molecular modelling, and in vitro validation of hERG activity.. 2022 , 142, 105247	0
86	Is Oral Lipid-Based Delivery for Drug Targeting to the Brain Feasible?. 2022 ,	1
85	Application and Utility of Liposomal Neuroprotective Agents and Biomimetic Nanoparticles for the Treatment of Ischemic Stroke.. 2022 , 14,	2
84	Nanomaterial Probes for Nuclear Imaging.. 2022 , 12,	2
83	Alzheimer's Disease (AD): Physiological Barriers for Therapy and Nanotechnological Applications in Treatment. 2021 , 215-237	
82	Memory enhancement effect of saponins from leaves and blood-brain barrier-permeated saponins profiling using a pseudotargeted monitoring strategy.. 2022 , 13, 3603-3620	1
81	Biosurfactants role in nanotechnology for anticancer treatment. 2022 , 375-395	
80	Current Status of In vitro Models of the Blood-Brain Barrier.. 2022 ,	
79	Recent advances in Bio-conjugated nanocarriers for crossing the Blood-Brain Barrier in (pre-)clinical studies with an emphasis on vesicles.. 2022 ,	5

78	Enhancing autophagy in Alzheimer's disease through drug repositioning.. 2022 , 237, 108171	4
77	Atomistic Model of Solute Transport across the Blood-Brain Barrier.. 2022 , 7, 1100-1112	1
76	The Bradykinin B2 Receptor Agonist (NG291) Causes Rapid Onset of Transient Blood-Brain Barrier Disruption Without Evidence of Early Brain Injury.. 2021 , 15, 791709	0
75	Targeting nucleic acid-based therapeutics to tumors: Challenges and strategies for polyplexes.. 2022 ,	1
74	Data_Sheet_1.docx. 2018 ,	
73	Table_1.docx. 2020 ,	
72	Yttrium Oxide Nanoparticles Moderate the Abnormal Cognitive Behaviors in Male Mice Induced by Silver Nanoparticles.. 2022 , 2022, 9059371	
71	Clinical advances of RNA therapeutics for treatment of neurological and neuromuscular diseases.. 2022 , 19, 594-608	2
70	Alpha-Synuclein Targeting Therapeutics for Parkinson's Disease and Related Synucleinopathies. 2022 , 13,	3
69	Modeling the blood-brain barrier for treatment of central nervous system (CNS) diseases.. 2022 , 13, 204173142210959	
68	Both the Complexity of Tight Junctions and Endothelial Transcytosis Are Increased During BBB Postnatal Development in Rats.. 2022 , 16, 850857	
67	Increasing Brain Exposure of Antibodies. 2022 , 27-69	
66	Drug Delivery to the CNS in the Treatment of Brain Tumors: The Sherbrooke Experience. 2022 , 551-576	
65	Blood-brain barrier-on-a-chip for brain disease modeling and drug testing. 2022 , 55, 213-219	1
64	Applications of Gold Nanoparticles in Brain Diseases across the Blood-Brain Barrier.. 2022 , 29,	
63	Brain Drug Delivery and Neurodegenerative Diseases: Polymeric PLGA-Based Nanoparticles as a Forefront Platform. 2022 , 101658	1
62	Structure, function and mechanistic aspects of scorpion venom peptides - A boon for the development of novel therapeutics. 2022 , 100068	0
61	Evaluation of the therapeutic effect of mesoporous silica nanoparticles loaded with Gallic acid on reserpine-induced depression in Wistar rats. 2022 , 23,	0

60	Penetration of Organophosphate Triesters and Diesters across the Blood-Cerebrospinal Fluid Barrier: Efficiencies, Impact Factors, and Mechanisms. 2022 , 56, 8221-8230	1
59	Benefits and limitations of nanomedicine treatment of brain cancers and age-dependent neurodegenerative disorders. 2022 ,	0
58	Therapeutic ultrasound: The future of epilepsy surgery?. 2022 ,	1
57	Transport of cationic liposomes in a human blood brain barrier model: Role of the stereochemistry of the gemini amphiphile on liposome biological features. 2022 , 627, 283-298	2
56	Endothelial Antibody Factory at the Blood Brain Barrier: Novel Approach to Therapy of Neurodegenerative Diseases. 2022 , 14, 1418	0
55	The emergence of the calvarial hematopoietic niche in health and disease.	1
54	Inhibiting Metastasis and Improving Chemosensitivity via Chitosan-Coated Selenium Nanoparticles for Brain Cancer Therapy. 2022 , 12, 2606	0
53	Alzheimer's and Parkinson's disease therapies in the clinic.	1
52	Specific anti-glioma targeted-delivery strategy of engineered small extracellular vesicles dual-functionalised by Angiopep-2 and TAT peptides. 2022 , 11,	1
51	Long-Circulation and Brain Targeted Isoliquiritigenin Micelle Nanoparticles: Formation, Characterization, Tissue Distribution, Pharmacokinetics and Effects for Ischemic Stroke. Volume 17, 3655-3670	
50	A merged molecular representation deep learning method for blood-brain barrier permeability prediction.	2
49	Nanocarrier facilitated drug delivery to the brain through intranasal route: A promising approach to transcend bio-obstacles and alleviate neurodegenerative conditions. 2022 , 75, 103656	1
48	Hinokitiol functions as a ferroptosis inhibitor to confer neuroprotection. 2022 , 190, 202-215	1
47	Liposomal formulations for treating lysosomal storage disorders. 2022 , 190, 114531	0
46	Development of Brain-Tumor-Targeted Benzothiazole-Based Boron Complex for Boron Neutron Capture Therapy.	0
45	Directing the Way: Receptor and Chemical Targeting Strategies for Nucleic Acid Delivery.	1
44	Pretargeted Imaging beyond the Blood-Brain Barrier: Utopia or Feasible?. 2022 , 15, 1191	1
43	Intracerebroventricular administration of oxytocin and intranasal administration of the oxytocin derivative improve β -amyloid peptide (25B5)-induced memory impairment in mice.	1

- 42 Brain metastases: It takes two factors for a primary cancer to metastasize to brain. 12, 0
- 41 Overcoming the blood-brain barrier for the therapy of malignant brain tumor: current status and prospects of drug delivery approaches. **2022**, 20, 4
- 40 Choroid plexus-derived extracellular vesicles exhibit brain targeting characteristics. **2022**, 121830 0
- 39 Theranostic Nanomaterials for Brain Injury. **2022**, 307-350 0
- 38 Medical micro- and nanomotors in the body. **2022**, 1
- 37 The Use of Photodynamic Therapy in the Treatment of Brain Tumors—A Review of the Literature. **2022**, 27, 6847 2
- 36 Computational Study of Magnetic Particle Motion inside the Nasal Cavity under the Impact of an External Magnetic Field for Biomedical Applications. **2022**, 13, 1816 0
- 35 The development and function of the brain barriers—an overlooked consideration for chemical toxicity. 4, 0
- 34 Dendrimers in the effective management of Alzheimer's and dementia. **2023**, 71-88 0
- 33 Editing a gateway for cell therapy across the blood-brain barrier. 0
- 32 Pretargeted Imaging Beyond the Blood-Brain Barrier. 1
- 31 Brain endothelial cells acquire blood-brain barrier properties in the absence of Vegf-dependent CNS angiogenesis. **2023**, 494, 46-59 0
- 30 CRISPR/Cas9 targeting liposomes knocked down multidrug resistance proteins in brain endothelial cells as a model to predict potential pharmacoresistance. **2023**, 222, 113103 0
- 29 Label-Free Assessment of Mannitol Accumulation Following Osmotic Blood-Brain Barrier Opening Using Chemical Exchange Saturation Transfer Magnetic Resonance Imaging. **2022**, 14, 2529 0
- 28 Transcription factor ZNF22 regulates blood-tumor barrier permeability by interacting with HDAC3 protein. 15, 0
- 27 In vivo methods for imaging blood-brain barrier function and dysfunction. 1
- 26 In Silico Proof of the Effect of Quercetin and Umbelliferone as Alpha-Amylase Inhibitors, Which Can Be Used in the Treatment of Diabetes. 202-216 0
- 25 Vascular endothelial cells: a fundamental approach for brain waste clearance. 0

- 24 Polymer-Based Drug Delivery Systems Under Investigation For Enzyme Replacement And Other Therapies Of Lysosomal Storage Disorders. **2023**, 114683 ○
- 23 Recent developments in multifunctional neural probes for simultaneous neural recording and modulation. **2023**, 9, ○
- 22 A Photoacoustic Probe with Blood-Brain Barrier Crossing Ability for Imaging Oxidative Stress Dynamics in the Mouse Brain. ○
- 21 A Photoacoustic Probe with Blood-Brain Barrier Crossing Ability for Imaging Oxidative Stress Dynamics in the Mouse Brain. ○
- 20 MODELING.Vis: A Graphical User Interface Toolbox Developed for Machine Learning and Pattern Recognition of Biomolecular Data. **2023**, 15, 42 ○
- 19 Advances in Antibody-Based Therapeutics for Cerebral Ischemia. **2023**, 15, 145 ○
- 18 Netrin-1 binding to Unc5B regulates Blood-Retina Barrier integrity. ○
- 17 Effect of P-Glycoprotein on the BloodBrain Barrier Transport of the Major Active Constituents of Salvia miltiorrhiza Based on the MDCK-MDR1 Cell Model. ○
- 16 Transporter-Mediated Drug Delivery. **2023**, 28, 1151 ○
- 15 Role of AI in ADME/Tox toward formulation optimization and delivery. **2023**, 301-345 ○
- 14 Angiopep-2-conjugated FeTi@Au core-shell nanoparticles for tumor targeted dual-mode magnetic resonance imaging and hyperthermic glioma therapy. **2023**, 102673 ○
- 13 Safety Profile of Low-Intensity Pulsed UltrasoundInduced BloodBrain Barrier Opening in Non-epileptic Mice and in a Mouse Model of Mesial Temporal Lobe Epilepsy. **2023**, 49, 1327-1336 ○
- 12 In-vivo time course of organ uptake and blood-brain-barrier permeation of poly(L-lactide) and poly(perfluorodecyl acrylate) nanoparticles with different surface properties in unharmed and brain-traumatized rats. 14, ○
- 11 Polymeric Metal Contrast Agents for T1-Weighted Magnetic Resonance Imaging of the Brain. **2023**, 9, 1224-1242 ○
- 10 Enhancing Methotrexate Delivery in the Brain by Mesoporous Silica Nanoparticles Functionalized with Cell-Penetrating Peptide using in Vivo and ex Vivo Monitoring. **2023**, 20, 1531-1548 ○
- 9 Towards Standardisation of a Diffuse Midline Glioma Patient-Derived Xenograft Mouse Model Based on Suspension Matrices for Preclinical Research. **2023**, 11, 527 ○
- 8 Carbon Nanomaterial-Based Biosensors: A Forthcoming Future for Clinical Diagnostics. **2023**, 1067-1089 ○
- 7 Effectiveness of ALK inhibitors in treatment of CNS metastases in NSCLC patients. **2023**, 55, 1018-1028 ○

- 6 Interactions of Graphene Oxide and Few-Layer Graphene with the BloodBrain Barrier. **2023**, 23, 2981-2990 ○
- 5 Advanced nanoformulations for neurological therapeutics. **2023**, 677-709 ○
- 4 Insulin-like growth factor-2 is a promising candidate for the treatment and prevention of Alzheimer's disease. ○
- 3 Radiosensitisation by olaparib through focused ultrasound delivery in a diffuse midline glioma model. **2023**, 357, 287-298 ○
- 2 Lipid nanocarriers for the delivery of drugs to the nervous system. **2023**, 109-126 ○
- 1 Bispecific antibody shuttles targeting CD98hc mediate efficient and long-lived brain delivery of IgGs. ○